A study towards the synthesis of a hybrid bioartificial liver by Vally, Tasneem
  
 
 
 
 
A STUDY TOWARDS THE SYNTHESIS OF A HYBRID 
BIOARTIFICIAL LIVER 
 
 
 
 
 
 
 
 
Tasneem Vally 
 
 
 
 
A STUDY TOWARDS THE SYNTHESIS OF A HYBRID 
BIOARTIFICIAL LIVER 
 
 
Tasneem Vally 
 
 
A thesis submitted to the Faculty of Engineering and the Built Environment, 
University of the Witwatersrand, Johannesburg, in fulfilment of the requirements for 
the degree of Doctor of Philosophy. 
 
 
Johannesburg, 2004 
 
I
DECLARATION 
 
I declare that this thesis is my own, unaided work, except where otherwise 
acknowledged.  The thesis is being submitted for the degree of Doctor of Philosophy 
at the University of Witwatersrand, Johannesburg. This thesis has not been submitted 
before for any degree or examination at any other university. 
 
 
 
Signed this _____ day of ____________ 20____ 
 
 
 
 
 
 
_____________________ 
Tasneem Vally 
 
II
ABSTRACT 
 
If one were to imagine the body as a chemical processing plant, then the liver would 
be equated to the reactor responsible for almost all the metabolic activities of the 
body. There is hardly any chemical produced, secreted or regulated that the liver is 
not directly or indirectly responsible for, making the design of an artificial liver a 
daunting task for any researcher. It is currently impossible to replicate the multitude 
of functions of a single liver cell, even given all the knowledge and technological 
advances of the 21st century. 
 
An artificial liver should be able to supplement the failing functions, especially those 
of a detoxification nature, of an injured or diseased liver. This can be achieved by 
harnessing the natural capabilities of transformed hepatocytes for use in a hybrid 
artificial liver. Today, even with all the research currently taking place, liver 
transplantation is still the most common response to acute or chronic liver failure. 
The aim of this study was to develop a feasible theoretical design for a hybrid 
artificial liver reactor. This study draws on various disciplines such as biochemistry, 
medicine and engineering. A high-level systems approach was employed to the 
Process Synthesis. Process Synthesis methodology ensures efficiency in the design 
process which is achieved by conducting the laboratory experiments in parallel with 
the reactor or process design such that only those experiments or parameters that 
require optimisation need to be performed. 
 
The capability of the selected transformed hepatocyte cell lines, HuH7 and HepG2 for 
specific liver functions; the intrinsic cells kinetics for the two cell lines and the 
sensitivity of the reactor design to the cell line incorporated were determined. The 
three liver function tests selected were: ammonia metabolism, lignocaine uptake and 
99mTc-DISIDA uptake. Our laboratory data demonstrate that for all three functions, 
both the cell lines exhibit liver functionality and that their kinetics are fairly similar. 
This finding suggests that the type of cell line incorporated in the reactor does not 
 
III
appear to significantly impact on the reactor design. Hence, it would appear from the 
preliminary screening tests that the choice of cell line incorporated is not a key 
parameter. Since Chang’s method of immuno-isolation by microencapsulation was 
employed, the kinetics of external mass transfer was compared to the intrinsic cell 
kinetics to determine the rate-limiting step. Results indicate that the capsular 
membrane does not significantly impede mass transfer and that intrinsic cell kinetics 
is the rate-limiting step. The research has demonstrated that a packed bed 
configuration is a feasible reactor type capable of including the number of cells 
neccesary to effect the reaction rate essential for the adequate removal of substances 
required for artificial liver support.  
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1.  INTRODUCTION 
 
1.1 INTRODUCTION TO THE THESIS 
 
As a young naïve graduate student the choice of topic for pursuing postgraduate 
research studies at the University of the Witwatersrand, Johannesburg seemed easy. 
(The gravity of the decision was endured much later into the studies). The appeal of 
being a pioneer, researching in a fairly new field at the University was all too 
tempting to resist. Biomedical engineering appeared as an exciting alternative to 
distillation. Since the university did not have a Biomedical Engineering department, 
expert supervision had to be sourced from various avenues. Within this context, 
expertise was sourced in the form of my supervisors: Professor Diane Hildebrandt 
and Professor David Glasser from the field of Chemical Engineering; Dr David 
Rubin, a medical doctor with a background in Electrical Engineering and Biomedical 
Engineering; and Professor Nigel J. Crowther, Associate Professor of Chemical 
Pathology at the University of the Witwatersrand Medical School. 
 
Developing a bioartificial hybrid liver reactor required input from each of these 
disciplines. It was of paramount importance that the questions raised in each of these 
areas were addressed by the research. We had the daunting task of consolidating this 
hybrid mass of work in such a way that it would satisfy both the engineering and 
medical realms. To this end, a high-level systems approach was employed to the 
Process Synthesis. 
 
Process Synthesis methodology ensures efficiency in the design process. This is 
achieved by conducting the laboratory experiments in parallel with the reactor or 
process design. This implies that only those experiments or parameters that require 
optimisation need to be performed, saving the researcher the time and costs of 
unnecessary laboratory work. 
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The literature review elucidated the various approaches that have been pursued in 
terms of developing artificial liver support. Since the late 1950s’ work in this 
particular area has been ongoing, with not a single device achieving widespread 
clinical application. Questions such as the best way to introduce liver functionality 
into the reactor without the need for immunosuppression; or the sensitivity of the 
reactor design to the biological component; the rate limiting reaction; how the rate-
limiting step influences or affects the reactor design; and what reactor type is most 
feasible for a Hybrid Artificial Liver Reactor (HALR) forged the direction of the 
research. 
 
Many more questions were raised in each of the avenues investigated, and further 
research could have been carried out in order to take the arguments further, but only 
those issues that had a direct impact on the reactor design were investigated.  
 
All research conducted was consolidated into three independent research papers, 
submitted or accepted for publication in a peer reviewed journal and presented at 
various international conferences. Each of these papers appears as a chapter in this 
thesis, which can be read independently. Each chapter consists of an abstract, its own 
literature review, introduction and conclusions. Subsequently, the reader may find 
some repetition or redundancy. The author begs your patience in this regard. 
 
1.2 OVERALL LITERATURE REVIEW 
 
1.2.1 Liver Biochemistry 
 
The liver is the largest gland in the body, weighing approximately 1500 grams in an 
adult. Owing to its great vascularity, wounds of the liver cause considerable 
haemorrhage. The liver is the only internal organ of the human body capable of 
regeneration (WILLIAMS et al., 1989). 
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 igure 1.2.1.1: Anterior view of the liver reprinted from www.livercancer.com 
eveloping a bioartificial hybrid liver reactor required input from each of these 
rocess Synthesis methodology ensures efficiency in the design process. This is 
iver function is manifold, involving: 
etabolism (glyconeogenesis and glycogenolysis); 
 Synthesis of lipoproteins and cholesterol; 
F
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disciplines. It was of paramount importance that the questions raised in each of these 
areas were addressed by the research. We had the daunting task of consolidating this 
hybrid mass of work in such a way that it would satisfy both the engineering and 
medical realms. To this end, a high-level systems approach was employed to the 
Process Synthesis. 
 
P
achieved by conducting the laboratory experiments in parallel with the reactor or 
process design. This implies that only those experiments or parameters that require 
optimisation need to be performed, saving the researcher the time and costs of 
unnecessary laboratory work. It is commonly agreed, however, that the liver's main 
purpose is the maintenance of homeostasis (WILLIAMS et al., 1989). 
 
L
 Detoxification; 
 Carbohydrate m
 Fat and lipid metabolism; 
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 Protein metabolism; 
 Synthesis of plasma proteins (albumin, fibrinogen, coagulation 
obulin); 
• 
• s have enzymatic function in the plasma and 
 Coagulatio
 Storage of Essential Nutrients and Vitamins; 
aceuticals and Vitamins, and 
 
Figure 1.2.1.2
 
Need for Artificial Liver Support 
epending on the amount of time the liver 
kes to fail. Liver failure is caused either by trauma, extensive injury or disease. 
Severe liver disease affects the body’s ability to adequately sustain the various 
metabolic functions discussed previously. This prevents other organs in the body 
factors, transferrin, gl
• Albumin accounts for colloid osmotic pressure in the 
plasma, 
Fibrinogen is crucial to blood clotting, 
Globulin
enhance immunity; 
n of Bile Acids; 
  Biotransformation of Pharm
 Immunity (WILLIAMS et al., 1989). 
 Basic structure of a liver lobule (Reprinted from GUYTON, 1960) 
1.2.2 
 
Hepatic failure is either acute or chronic, d
ta
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from efficiently and adequately performing their functions. Fulminant hepatic failure 
(FHF) is defined as severe acute liver failure complicated by encephalopathy that 
develops within 8 weeks of the onset of symptoms. In FHF, the time course from 
onset of illness to death is approximately 10 days with a survival rate of 10-15% at 
best (DIXIT & GITNICK, 1996).  
 
Hepatic encephalopathy occurs primarily as a consequence of a failure of the liver to 
adequately detoxify substances that are neurotoxic. Toxic substances include 
ammonia, short chain fatty acids, mercaptans and phenols (MATSUSHITA & NOSE, 
986). An artificial liver should have the ability to remove these toxins from 
hepatectomy. Subsequent rounds 
f cell division are not as well coordinated, but the liver can double its hepatocyte 
nsplantation. These include venovenous bypass, caval anastomosis, arterial 
nd venous grafts as well as the development of split, auxiliary (HEATON, 2002) and 
1
circulation. The simplest means to artificially mimic liver function is to incorporate 
cells – an example would be transformed hepatocytes, which possess this inherent 
ability, into the design of the artificial liver reactor. 
 
The regenerative capacity of the liver is enormous and is the foundation of recovery 
from FHF. Studies involving rats demonstrate that almost every hepatocyte undergoes 
a round of cell division about 20 hours after partial 
o
mass in less than 1 day, which is critical in the treatment of FHF. Even patients with 
advanced disease may recover rapidly once regeneration begins, and those who 
recover have no residual liver disease and a normal life expectancy (SUSSMAN, 
1996). 
 
Since the first human cadaveric liver transplantation took place in 1963, there have 
been a number of advances in surgical technique, which has dramatically changed 
liver tra
a
living donor liver transplantation (SAPA-AP, 2003). 
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Today, even with all the research currently taking place, liver transplantation is still 
the most common response to acute or chronic liver failure. Rejection of the 
ansplanted tissue is a frequent outcome, and its control with suppression of the 
immune system opens the door to a long list of undesirable side effects. In 1988, the 
United States had 2329 patients on the UNOS (United Network of Organ Sharing) 
liver waiting list, while in 1995 this number increased 5 fold to 10 529. The number 
of deaths whilst awaiting orthotopic liver transplantation (OLT) had increased from 
196 in 1988 to 254 in 1995 (MEMON, 2000). OLT means replacement of a 
potentially self-regenerating organ with a lifetime application of immunosuppression 
and risk of complications such as rejection of the organ. The shortage of viable donor 
livers and the cost, difficulty and trauma associated with the transplantation, add to 
the problems encountered with this approach (FOUAD, 1996). 
 
The amount of liver tissue required providing adequate bioactive support is difficult 
to be determined. Anecdotal reports indicate that as little as 10% of total liver mass is 
compatible with preservation of life. Even in the most severe form of liver failure, 
there is always a certain amount of residual liver function and as little as 3-5% of 
additional liver mass in a liver support system could potentially make a difference 
(REDDY, 2001). Based on surgical resections, it is estimated that 20-40% of normal 
hepatocyte mass is necessary to sustain life. This corresponds to approximately 300g 
of hepatocytes if the patient weighs 70kg (LIU, 2002). 
tr
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 1.2.3 Advances in Hybrid Bioartificial Liver Devices 
 
“Fegato artificiale” as a concept of liver support, was first introduced by Sorentino in 
1956 (MATSUSHITA & NOSE, 1986). He demonstrated the detoxifying potential of 
fresh liver homogenate. Since then alternatives to whole organ transplantation as a 
possibility for treatment of liver dysfunction have been fervently investigated.  
 
Early attempts used cross circulation of blood from one individual through the liver 
of another individual or mammal. These techniques were associated with several 
adverse events and have not been generally accepted (LIU et al, 2002). In 1995 a 
patient regained consciousness in the third hour of a four-hour ex vivo porcine liver 
erfusion (FOUAD, 1996). A similar incident occurred with a patient’s blood being 
nsplantation, auxiliary partial 
liver transplantation, xenotransplantation, 
b. extracorporeal methods: human and xenogeneic liver perfusion and 
hybrid liver support (biochemically active liver cells cultivated in 
bioreactors and perfusion circuits.(IRGANG, 2002; KIMURA, 1980) 
 
 
 
                                                
p
perfused through the livers of four dogs. Obviously the idea of dogs around a 
patient’s bed is not the most practical approach, albeit an entertaining image. 
 
The various methods of support treatments include: 
1. detoxification methods 1: extracorporeal blood or plasma treatment, dialysis, 
heamofiltration, charcoal or resin perfusion, heamodialysis; 
2. biological treatments which support the regulatory liver functions: 
a. intracorporeal methods: hepatic cell tra
 
1 Haemodialysis may however have an adverse effect on cardiac output and other haemodynamic 
parameters leading to increased cerebral oedema (LIU, 2002). 
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The reason most non-biological approaches have met with little success is because 
the synthetic and metabolic functions of the liver are absent. The important synthetic 
on he only function of the 
ioartificial devices incorporate isolated cells into bioreactors to simultaneously 
array of 
nown functions will also express those unknown functions that may perhaps be 
 
Primar limited in supply. 
The plantation. 
The growth lim
can proliferate functions. Cell lines derived 
from hepat u
clinical trials (ELAD®). In the c
transmission h , 
tem cells are being considered for liver disease therapy. Potential sources include 
mbryonic stem cells, adult liver progenitors and trans-differentiated non-hepatic 
ells (ALLEN, 2001). 
functi s of the liver can be intravenously administrated. T
liver that cannot be supported nor substituted is that of detoxification. Haemodialysis, 
Haemoperfusion over charcoal, resins and immobilised enzymes, plasmapheresis and 
plasma exchange have all been explored (ALLEN, 2001). 
 
B
promote cell survival and function as well as provide for a level of transport seen in-
vivo (ALLEN, 2001). The biochemistry of the liver is enormous and the full 
complement of hepatocyte functions required in a BAL to effect positive clinical 
outcomes has not yet been completely determined. To address this problem, certain 
liver function tests believed to be essential to aid a failing liver have been employed 
as markers of adequate liver functionality and therefore of adequate cellular 
components. The implicit assumption is that hepatocytes capable of a wide 
k
essential in liver metabolism (ALLEN, 2001). 
y liver cells would be ideal, but like whole organs, they are 
y have been used for BAL application as well as for hepatocyte trans
itations of primary cells has spurred attempts to develop cell lines that 
 in culture while maintaining liver specific 
ic t mours such as C3A (a subclone of HepG2), have already been used in 
ase of tumour derived cell lines, filters preventing 
ave been implemented in the BAL design as extra precaution. Finally
s
e
c
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Continued innovation in engineering and material science has greatly contributed to 
the development of extracorporeal liver assist devices. It was the amazing burst of 
creative engineering called artificial organ science that presented to the world the first 
working artificial kidney, the heart-lung machine, cardiac valves, pacemakers, and 
corneal, hip, and arterial prosthesis in only a decade. However the development of 
such devices, which are effective for liver support have proven more elusive. New 
iscoveries in hepatocyte sourcing and stabilisation coupled with engineering d
innovation are quickly making BAL devices tailored for use with hepatocytes a 
reality.  
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The four main types of BAL devices each with their inherent advantages and 
disadvantages are: 
 Hollow Fibre 
Device 
Flat Plate and 
Monolayer 
Perfused Beds 
and Scaffolds 
Encapsulation 
and Suspension 
Advantages  Well 
characterised 
from dialysis 
application  
 Attachment 
surface 
 Potential for 
immunoisolat
 Uniform cell 
distribution 
and 
microenviron
ment 
 
 Ease of 
scale up 
 Promotes 
3D 
architecture 
 Minimal 
transport 
barrier 
 Minimal 
transport 
barrier-Better 
mass transfer 
 Best surface 
area to 
volume ratio 
 Scalability 
ion  Potential to 
mimic in 
vivo 
microenviron
ment 
 Use of whole 
blood 
perfusion 
Disadvantages  Non uniform 
cell 
distribution 
 Mass transfer 
limitations 
imposed by 
membranes 
 Scale up, 
design 
constraints 
volume of 
cells 
 Plasma 
instead of 
whole blood 
perfusion 
 Complex 
scale up 
 Potential 
large dead 
volume 
 Cells exposed 
to shear 
 Low surface 
area to 
volume ratio 
 
 Non 
uniform 
perfusion 
 Clogging 
 Cells 
exposed to 
sheer forces 
 Degradation 
of 
microcapsule
s over time 
 Potential 
exposure to 
shear forces 
if excessive 
superficial 
velocities are 
used. 
 
Table 1.2.3.1: Advantages and disadvantages of current BAL designs 
 
A successful and clinically effective BAL device should satisfy a few key criteria: 
 Adequate bi-directional mass transport; 
 Maintained cell viability and function; 
 Potential for scale up to therapeutic levels. 
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Bidirectional Mass Transfer 
In BAL devices, bi-directional mass transfer is required to provide nutrients to sustain 
ell viability an val of oduc
Cell viability and fu
One of the major o  BAL o -term
maintain highly functional hepatocytes in-vitro. Cu n  designs
mimic in-vivo micro t of normal liver cells. 
 
Scale up 
For a device to become a clinical reality it must be scaled up to a size that provides 
effective therapy. Studies indicate that between 10 and 30% of liver cell mass is 
st  l sl s to 45  o s neede n 
 
c d allow remo  metabolic pr ts. 
 
nction 
bstacles to ffering long  treatment is the inability to 
rre t device  do little to 
environmen
required to su ain ife. This tran ate  into 150 0g f cell d i a device. 
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2. CHAPTER 
 
De
to the Choice of Cell
 
 
This chapter was written in the form of a paper for publication. Certain sections of 
this paper were also presented at the World Congress on Medical Physics and 
Biomedical Engineering (WC2003) held under the auspices of the International 
Federation for Medical and Biological Engineering, held in Sydney, Australia, 
August 24-29 2003. 
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uld be able to supplement the failing functions, especially those 
f a detoxification nature, of an injured or diseased liver. This can be achieved by 
lities of transformed hepatocytes for use in a hybrid 
rtificial liver. The aims of this study were to determine the capability of the selected 
ansformed hepatocyte cell lines, HuH7 and HepG2 for specific liver functions; the 
intrinsic cells kinetics for the two cell lines and the sensitivity of the reactor design to 
the cell line incorporated. The three liver function tests selected were: ammonia 
metabolism, lignocaine uptake and 99mTc-DISIDA uptake. This was achieved by 
characterising the metabolic activities of both cell lines. Data demonstrate that for all 
three functions, both the cell lines exhibit liver functionality with respect to the 
initially mentioned tests and that their kinetics are fairly similar. The implication of 
this result is that the type of cell line incorporated in the reactor does not appear to 
significantly impact on the reactor design as the reaction rates are of the same order 
of magnitude. Hence, it would appear from the preliminary screening tests that the 
choice of cell line incorporated is not a key parameter. If the reaction rates obtained 
for the two cell lines with respect to the three tests differed significantly, more cell 
lines might have been tested for application in a Hybrid Artificial Liver Reactor 
(HALR). 
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2.1 INTRODUCTION 
 
The biological complexity of the liver is immense. Many of the specific processes 
volved with this organ's multiple functions are not yet fully understood. However, it 
antial regenerative capacity, an 
 
h a 
evice would provide, to a recovering liver. Our hybrid artificial liver design is a 
oth biological and synthetic components. The biological component that 
eeds to be considered is determining a suitable cell line to incorporate into the 
in
is commonly agreed that the liver's main purpose is the maintenance of homeostasis 
(WILLIAMS et al., 1989). As the liver has a subst
artificial liver could provide invaluable time to both patients awaiting liver
transplantation and those who would benefit from the reduced hepatic load, suc
d
chimera of b
n
reactor. 
 
2.1.1 Choosing a Cell Line/s 
 
A suitable reactor should be capable of providing and supplementing essential liver 
functions. This would provide reprieve to the diseased liver to recover and regenerate 
or in the case of a bridge to transplantation, mitigate the pathological effects of liver 
failure until a donor liver becomes available. The consensus among researchers 
evolving from the charcoal Haemoperfusion era has been to employ transformed 
hepatocytes (hepatoma cell lines) in their various reactor configurations 
(MATSUURA, et al, 1998). It must be added that the possible risks of using 
transformed cells still needs to be thoroughly investigated before any consideration of 
clinical trials can be envisaged, however, this aspect is not addressed in these in vitro 
studies. 
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The rationale behind using hepatoma cell lines is multifaceted. Firstly, a steady 
s of hepatocytes can be made available. Secondly, the 
choosing a cell line to be used in a 
 workshop sponsored by the National Digestive Disease Advisory Board concluded 
supply of very large quantitie
use of hepatoma cell lines allows us to harness the natural capabilities of liver cells, 
instead of attempting to artificially duplicate complex liver functions. Furthermore, it 
is not possible to keep long-term primary cell cultures of hepatocytes because 
hepatocytes start to dedifferentiate within a week of culture (DIXIT & GITNICK, 
1996). Thirdly, hepatoma cells can be maintained in vitro indefinitely without loss of 
functionality. Primary cells have a limited in vitro life span even though they may 
have important hepatic functions. A steady supply of fresh cells is required, and cell 
isolation is technically challenging and time consuming. A human immortalised cell 
line is an attractive alternative as cell division is practically unlimited.  
 
What factors should be considered when 
bioartificial liver device? 
A
that the ideal hepatocyte for cell-based extracorporeal devices should be human in 
origin, rapidly and easily grown in culture at high densities and of normal (non-
malignant) phenotype. These cells should remain in a well-differentiated state for 
days or weeks, and consequently, they must display synthetic and detoxifying 
features of mature hepatocytes (JAUREGUI, 1999). As with most differentiated cells, 
pure populations of hepatocytes exhibit phenotypic changes resulting in alterations of 
specific cell functions early in their life span in vitro (CLEMENT et al., 1984; 
NAKABAYASHI, et al., 1984). 
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Isolated porcine hepatocytes have been used in certain bioartificial liver reactor 
configurations (MIYASHITA, 2000). Swine has been exploited as a source of 
hepatocytes due to the availability and the accumulation of biological knowledge of 
the species (MIYASHITA, 2000). However, they do not provide a viable alternative 
to primary cells due to the problems associated with porcine cells (MIYASHITA, 
2000): 
1. functional hepatocytes are only cultured for several days, 
2. viability and function are affected by cryopreservation, 
3. risk of porcine endogenous retroviral infection. 
Research in developing the “perfect cell line” with extended culture capability for 
incorporation in a liver device is ongoing (TALBOT, 1999). 
 
The cells incorporated in our reactor design were chosen by virtue of their ability to 
mimic selected liver functions both qualitatively and quantitatively. The functional 
min, prealbumin, α1-antitrypsin, ceruloplasmin, 
brinogen, fibronectin, haptoglobin, hemopexin, β2-microglobulin, transferrin, 
complement components 3 and 4 and α1-fetoprotein. The HuH-7 cell line does not 
contain the hepatitis B surface antigen (NAKABAYASHI, et al., 1982). The HuH-7 
cell line has been reported to produce the highest amount of AFP when compared to 
other human hepatoma cell lines (NAKABAYASHI, et al., 1984). 
integrity of two cells lines, HuH-7 and HepG2, were determined based on three labile 
liver function tests. These were ammonia metabolism, lignocaine uptake by the P450 
hepatic system and 99mTc-DISIDA uptake by the bilirubin pathway. 
 
Research by Nakabayashi et al (1984) demonstrated that the HuH-7 cell line exhibits 
a stable phenotypical expression of some differentiated liver functions in long term 
cell culture. These cells produced a number of plasma proteins, liver specific 
enzymes and bile acids. The HuH-7 cell line is reported to produce the following 
human plasma proteins: albu
fi
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HepG2 retains hepatic functions well compared to other hepatic cell lines 
(MIYASHITA, 2000). Studies by NAGAKI, et al., (2000) indicate that HepG2 cells 
are capable of ureagenesis. The following HepG2 products have been reported by the 
ATCC [14]: α1-fetoprotein, albumin, α1-antichymotrypsin, α1-antitrypsin, 
complement components 3 and 4 and fibrinogen, among others. C3A is a clonal 
derivative of HepG2, which exhibits strong contact inhibition of growth and high 
alb and have nitrogen-
met  HepG2 and C3A (a 
clo  preferred cell lines of choice 
.1.2 Liver Function Tests 
hoice of cell line 
corporated. Therefore, only two cell lines were initially tested, namely, HuH-7 and 
umin production. The cells display gluconeogenesis activity 
abolizing activity comparable to perfused rat livers [14].
nal derivative of HepG2) have been included as the
in Kelly’s liver assist device (LAD) (Kelly, 1994).  
 
2
 
The aim of this study was not to determine or develop the best cell line to be 
employed, but to investigate whether a significant difference exists in the metabolic 
and the uptake rates between different cell lines. Initial kinetic determination was 
aimed at establishing the sensitivity of the reactor design to the c
in
HepG2. If the rates determined differed significantly between the cell lines, for the 
selected liver tests, then more cell lines might have been tested. Liver function 
comprises many diverse reactions all of which relate to the maintenance of 
homeostasis (WILLIAMS, 1989). The functions we chose to test include ammonia 
metabolism, which is a stringent test of hepatocyte integrity; P450 activity (in the 
form of lignocaine uptake), which relates to the detoxification capability of the 
hepatocytes and bilirubin removal using an analogue, 99mTc-DISIDA, shown (Okuda, 
1986) to employ the same uptake pathway as bilirubin. 
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2.2 METHOD AND MATERIALS 
 
Hepatocyte Sub-Culturing Procedure: 
 
Hepatocytes (HuH-7, HepG2) were cultured in Dulbecco’s Modified Eagle’s Medium 
DMEM (1.0 mM sodium pyruvate, 2 mM L-glutamine, 0.1 mM non-essential amino 
acids, 1250 µL penicillin/ streptomycin) supplemented with 5-10% fetal calf serum. 
(All chemicals purchased from Sterilab Services, Kempton Park, South Africa). Spent 
medium was replaced every four days. 1.0ml of trypsin (Sterilab Services, Kempton 
Park, South Africa) solution was added to the flask and cells observed under an 
inverted light microscope until cell layer was dispersed (usually 5 – 15min). Note: 
agitating the cells by hitting or shaking while waiting 
r cells to detach. Cells that were difficult to detach were placed at 37oC to facilitate 
ml aliquots were added to 
ells were frozen overnight at –20oC. Frozen cells were transferred to 
liquid nitrogen. 
 
Clumping was avoided by not 
fo
dispersal. 3ml of complete tissue culture medium were added and mixed by gently 
pipetting. Appropriate aliquots of the cell suspension were added to new culture 
vessels, at dilutions ranging from 3 to 20 fold. Cell cultures were incubated at 37oC in 
a 95% air and 5% CO2 atmosphere. 
 
Method for Cryopreserving Cells: 
 
The cryoprotectant medium consists of Fetal Calf Serum (FCS) supplemented with 
10% Dimethyl Sulphoxide (DMSO). 1 ml of trypsin was added to detach cells from 
the flask. 3 ml of tissue culture medium was added after cell detachment to inhibit 
trypsin. Cells were counted using a haemocytometer. Cells were spun down for 5 min 
at 400 G. Supernatant was removed and discarded. Cells were suspended in 
cryoprotectant medium to yield 106cells/ ml and 1 
cryovials. C
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Hepatocyte Viability: 
 with trypan blue (Sterilab Services, Kempton 
ark, South Africa). Live hepatocytes exclude trypan blue. Both stained and 
 
Cells were trypsinised and then stained
P
unstained cells were counted and viability was calculated as follows: 
( ) ( ) 100% ×−=
Total
Total
N
aNViability  
where TotalN  is the total number of cells and a represents the number of dead 
(stained) cells. 
 
2.2.1 Ammonia Metabolism 
 
Ammonia has been implicated in hepatic coma (GERLACH, et al, 1989; HANKER, 
1993). We chose the metabolism of ammonia to urea as a test of the metabolic 
integrity of hepatocytes, because urea synthesis involves both cytoplasmic and 
mitochondrial cell functions. The determination of urea kinetics has been used as a 
measurable index of functionality both in the clinical and investigative realms 
(KAPLAN et al., 1999). Normal liver cells in vivo synthesise urea at a rate of 2-3 
6 ., 1999; ZUCKER et al., 1995). mol/ 10 cells/ 24hrs (YOON et alµ
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2.2.1.1  
 
Materials and Methods 
 cocktail for its 
urea content. 100µl aliquots were removed at specific time intervals (10min, 20 min, 
30 min, 1hr, 2hr, 24 hours, 40 hours) for urea analysis. Cell growth rate during the 
oved, cells trypsinised and counted under the haemocytometer. Cell 
ethod described above. Urea concentration in the 
ampled medium was determined colorimetrically (Cintra 5 UV-VIS Spectrometer) at 
 
 
 
 
Figure 2.2.1.2.1: Graph of urea concentration (mM) as a function of time for 
transformed cell lines HuH-7 and HepG2. 
 
HepG2 and HuH-7 cell lines were grown in 50mL culture flasks to approximately 
95% confluency. Spent medium was replaced by glutamine (60mM) supplemented 
DMEM. FCS was specifically excluded from the cell culture medium
course of the experiment was assumed to be negligible. At the end of the experiment, 
medium was rem
viability was determined as per m
s
340nm using the Merck Ecoline 25 ® Urea Kit (1.14855.0001), employing the 
GIDH-method, kinetic UV test. 
2.2.1.2  Results  
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 edium of the incubated cells was measured 
over a 24hr period. All experiments were conducted in triplicate. Data in Figure 
 indic th cells lines exhibit similar ureagenesis functionality, i.e. the 
bility to metabolise ammonia into urea. The rate at which urea is initially produced 
creases as the concentration of urea increases until the maximum reaction rate is 
ached after which the rate starts decreasing probably corresponding to the 
ecreasing reactant concentration (ammonia) (Figure 2.2.1.2.2). 
ased on the reaction stoichiometry, two ammonia molecules are required to produce 
 single urea molecule. Thus, if we assume that when the rate of urea production has 
ached zero, at approximately 2.5-3.0 mM urea, the ammonia has all been used up. 
e can assume an initial ammonia concentration of about 5-6 mM (say 5.5mM). 
 
 
 
 
 
 
 
Figure 2.2.1.2.2: Rate of urea production (nmol/106cells/min) as a function of 
concentration for HuH-7 and HepG2. (The dotted line indicates the average rate 
obtained in vivo). 
 
The concentration of urea in the culture m
2.2.1.2.1 ate that bo
a
in
re
d
 
B
a
re
W
Using this value, we can assign proposed values of ammonia concentration on the 
same axis as the urea concentration. 
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As previous cells is quoted in 
e literature (YOON et al., 1999; ZUCKER et al., 1995) as 2-3 µmol/106cells/24hrs, 
hich translates into 2.08 nmol/106cells/min. The rate at which normal cells 
ynthesise urea is an order of ss then the maximum rate of reaction 
9nmol/106cells/min for HuH-7 and 35nmol/106cells/min for HepG2) achievable by 
e transformed hepatoma cell lines tested. The average rate for normal cells is 
lustrated on Figure 2.2.1.2.2 by the rust-coloured dotted line.  
al liver would have to remove, 100 µmol/l is a reasonable initial 
stimate (illustrated on Figure 2.2.1.2.2. by the yellow shaded region). This 
es. 
ly mentioned, the urea production rate for normal liver 
th
w
s magnitude le
(2
th
il
 
The normal concentration range of ammonia in the blood is approximately 18-72 
µmol/l (HAWKER, 1993). So if one had to approximate, the maximum concentration 
(Cmax) that a norm
e
concentration is substantially lower than what the hepatoma cells are able to 
metabolise, as is demonstrated by the range of rates measured over ammonia 
concentrations, which are higher than 100 µmol/l. Note however, the reaction rates 
achieved by these hepatoma cells at these lower concentrations are not much higher 
than the normal liver rates previously quoted. However, the rates obtained were for 
cells, although hepatic in origin, are hepatoblastoma. Cancer cells are inherently 
highly active therefore may be able to achieve higher reaction rat
 
Furthermore, it is interesting to note that these cells seem able to function at these 
higher ammonia concentrations without appearing to be poisoned by them. If the 
human body is unable to tolerate these higher concentrations, it is probably because 
these levels of ammonia are toxic to other organs in the body.  
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2.2.2  Lignocaine Uptake 
 
The role of the liver in metabolic conversions of foreign compounds is particularly 
important in its susceptibility to chemical injury (SCHIFF, 7th edn). Drug 
biotransformation is one important function that is impaired in the presence of liver 
disease (SCHIFF, 7TH EDN). In general, the degradation of drugs that primarily 
undergo oxidative transformation is significantly impaired in the presence of liver 
 Since most pharmacological agents in use are biotransformed by oxidative 
central nervous system may precipitate encephalopathy (SCHIFF, 7  edn). 
et al., 
997; OKAMOTO 1998; EGUCHI et al., 1999; BURDELSKI et al., 1987; LOREC 
disease.
processes of the P450 system, this observation assumes considerable clinical 
relevance. In patients with acute or chronic liver disease, drugs that depress the 
th
 
Lidocaine (lignocaine) was synthesised for the first time in 1943. Since then it has 
been used as a local anaesthetic agent (STENSON et al., 1971). The study by Stenson 
et al (1971) was the first to demonstrate that the liver accounts for the majority of 
metabolism or removal of lidocaine in man. (NATION et al., 1979; STENSON et al., 
1971). Lignocaine is metabolised primarily by the liver cytochrome P450 system 
through oxidative N-dealkylation, the major initial metabolite in humans being 
MEGX (OELLERICH et al., 2001). MEGX, the primary metabolite of lignocaine has 
been employed by many studies as an index for liver function (TREDGER 
1
1994; OELLERICH et al., 1987). Within the context of developing an artificial liver, 
the cytochrome P450 dependent mixed function oxidases (MFO) capability of 
cultured hepatocytes is one of the most labile of functions in terms of lignocaine 
metabolism (ANDERSON et al., 1998). 
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Preliminary data on the survival rates of patients indicate that MEGX formation may 
rovide valuable prognostic information. Comparative studies with various 
e time of 
xperimentation, the metabolite MEGX was not available from any commercial 
. Experiments were conducted in triplicate. 
ignocaine concentration in the medium was determined by HPLC (Appendix A). 
 
p
established liver function tests, such as indocyanine green clearance and galactose 
elimination capacity, demonstrated that a single MEGX serum concentration obtained 
15 minutes after an intravenous administration of lidocaine, had a distinctly higher 
predictive value for the assessment of dysfunction than any of the other liver function 
tests (OELLERICH et al., 1987). 
 
It is reported that the MEGX concentration measured 15 minutes after the 
introduction of lignocaine reflects the initial formation rate of this metabolite very 
well (CHEN et al., 1992, TREDGER & SHERWOOD, 1997). At th
e
source. Since the decrease in lignocaine concentration would correspond to MEGX 
formation, the disappearance of lignocaine as a function of time was measured 
instead. Lignocaine concentrations were determined by adapting the HPLC method 
described by CHEN & co-workers (1992). The method is reported to be both 
reproducible and sensitive to both lignocaine and MEGX (CHEN et al., 1992). 
 
2.2.2.1  Materials and Methods 
 
Various concentrations (500, 800, 1000, 1500, 2000, 2500 ng/ ml) of lignocaine were 
prepared by serial dilution with tissue culture medium. HepG2 and HuH-7 cell lines 
were grown in 50ml culture flasks to approximately 85% confluency. Cells were 
incubated in 3ml of the lignocaine/medium cocktail. Samples were aliquoted at time 
intervals of 15, 30, 45 and 60 minutes
L
 
26
 At the end of the experiments, the medium was removed and cells trypsinised, 
counted and viability assessed. 
 
Chromatographic System 
HPLC system employed a UV detector set at 205nm, manual injector equipped with a 
100-µL sampling loop, a µBondapak C18 (300 x 3.9 mm I.D.) column (Millipore). 
hromatography was performed at room temperature using a mobile phase of C
acetonitrile- potassium dihydrogen phosphate buffer (pH 4.0) (14:86) at a flow-rate of 
1.3 ml/min. 
2.2.2.2. Results 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.2.2.1: Lignocaine concentration in cells versus time of incubation 
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te of uptake of lignocaine as a function of 
itial lignocaine concentration for transformed cell lines HuH-7 and HepG2 
he ability lture medium 
 order to test the P450 activity of these cells was investigated. Lignocaine 
oncentration in the medium was measured as a function of time for a period of 60 
inutes. Figure 2.2.2.2.1 illustrates the cellular uptake of lignocaine measured as a 
 time. It is evident that both cell lines are almost equally capable of 
moving lignocaine from solution with HepG2 performing marginally better.  
itial uptake rates (rmax,0) of lignocaine were calculated from the slopes of the 
umulative uptake curves for various initial concentrations of lignocaine in complete 
reflects the initial formation rate of MEGX, the lignocaine metabolite very well 
(CHEN et al., 1992, TREDGER & SHERWOOD, 1997). Results were expressed as 
nanomoles per 106cells per min as demonstrated in Figure 2.2.2.2.2. 
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For the computation of the kinetic constants, values for lignocaine, Rmax and 
oncentration [L] were fitted directly to the Hill equation: 
Equation 2.2.2.2.1 
te (nmol/106cells/min), 
Rmax is the maximal uptake rate (nmol/106cells/min), 
Km is the lignocaine concentration at half the maximal rate, 
L is the lignocaine concentration, 
h is the Hill Coefficient. 
e. As is 
vident from Figure 2.2.2.2.3 and Figure 2.2.2.2.4, the model explains the measured 
c
                                                                                                           
 
hLhK
hLR
r
m ][
][max
+
=
Where: r is the uptake ra
An iterative non-linear least squares fitting procedure was employed to determine the 
parameters of the mathematical curve describing the data set for each cell lin
e
data adequately. 
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Figure 2.2.2.2.4 Rate of lignocaine uptake by the HepG2 cell line fitted to the Hill 
Kinetic Model. 
 
 
 
 
Figure 2.2.2.2.3 Rate of lignocaine uptake by the HuH-7 cell line fitted to the Hill 
Kinetic Model. 
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The maximal rate was estimated at, Rmax= 0.22 nmol/106cells/min, with h=3.98 and 
m= 4.17 nmol/ml for HuH-7 and Rmax= 0.178 nmol/106cells/min, with h= 4.33 and 
m= 4.69 nmol/ml for HepG2 (Refer to Figures 2.2.2.2.3 and 2.2.2.2.4 for graphical 
presentation). 
he clearance of lignocaine by normal hepatocytes is quoted in the literature 
ARDMAN, 2001; KATZUNG, 2001) as 9.2 ml/min/kg for a 70kg adult male with 
 steady state infusion rate of 1-4 mg/min to maintain a therapeutic plasma 
oncentration of 2-6 µg/ml.  
igure 2.2.2.2.5: Hepatic removal rate of lignocaine in a healthy liver superimposed 
n the rate/concentration curve obtained for HuH-7 and HepG2 also indicating the 
erapeutic concentration of lignocaine maintained in blood. 
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How do the rates of normal hepatocytes in the body compare with the maximum rates 
measured for HuH-7 and HepG2? A summary is given below: 
 
rLiver  cells = 4.53 x 10-12 mol/106cells/min 
maxHuH7 = 0.22 x 10-9 mol/106cells/min 
maximum rate at which the two hepatoma cell lines can 
move lignocaine from solution. There are many other competing reactions that 
ccur in th
etabolism. We only introduce the experimental system, therefore 
aturating this pathway. It mak t the rate obtained could be higher 
an the average rate of normal cells quoted in the literature for the liver. In any 
vent, at these low therapeutic concentrations, it is difficult from our results to predict 
e rates at which these hepatoma cells would pe ssible to compute the 
te from the Hill model for therapeutic concentrations and compare them with 
ormal liver cell rates). 
s the concentration of lignocaine is increased, the rate of reaction increased 
aine are not toxic to the 
ver cells themselves. In the human body however the high concentrations most 
robably result in secondary organ toxicities. 
r
rmaxHepG2 = 0.178 x 10-9 mol/106cells/min 
 
The average rate at which normal liver cells remove lignocaine from blood is 
significantly slower than the 
re
o e liver which utilise the P450 enzyme pathway including lignocaine 
m d lignocaine into 
es sense then tha
rform (it is po
s
th
e
th
ra
n
 
A
accordingly until saturation and maximum rate occur at a concentration of around 
2500 ng/ ml. It is quite surprising that the cells performed so well at such high 
concentrations. Obviously, the high concentrations of lignoc
li
p
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2.2.3 Uptake of the Radionuclide 99mTc-DISIDA 
 
2.2.3.1  Materials and Methods 
 
Bilirubin represents a class of compounds that are bound to plasma proteins. Plasma 
epatic coma and should therefore be removed 
evice (MATSUMURA et al., 1987). An 
ccurate measure of bilirubin conjugation by hepatocytes is difficult, due to the fact 
emoglobin is split into globin and heme. The heme ring is 
pened to give a free iron and a straight chain of four pyrrole nuclei, which will 
or study was based on a radioisotope 
chnetium-99m, which is widely used in medicine [15]. It has a physical half-life of 
 hours (HARDMAN, 2001; HENKIN, 1996; HIBBARD, 1982). The chemical 
versatility of technetium-99m allows it to be incorporated into a range of biologically 
active substances to ensure that it concentrates in the tissue or cell of interest.  
bound toxins have been implicated in h
from circulation by the artificial liver d
a
that bilirubin conjugates in the presence of light. Random drift bilirubin values can 
result from variations in exposure to light, temperature, water and other 
environmental factors (BRUNI & CHANG, 1995). Therefore, kinetics of a suitable 
radioactive bilirubin analogue was studied instead.  
 
Bilirubin, the main bile pigment in most mammals, is the principal end product of 
haemoglobin degradation and subsequently heam catabolism (CUI et al., 2001). 
When red blood cells have out lived their life span of approximately 120 days, and 
become too fragile to exist longer in the circulatory system, their cell membranes 
rupture, and the released haemoglobin is phagocytised by tissue macrophages 
throughout the body. Ha
o
eventually form bilirubin. Bilirubin is a dicarboxylic acid characterised by minimal 
solubility at physiological pH. It is neither hydrophilic nor lipophilic, necessitating 
biotransformation by hepatocytes into a more polar conjugate for excretion (via 
secretion into bile)(ZUCKER, 1999; CUI et al., 2001).  
 
The radioactive bilirubin analogue selected f
te
6
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The criteria for an ideal radiopharmaceutical would be: 
 No reaction with hepatocytes occurs; 
 It has a short biological half life, and  
ISIDA was chosen for this study as it presents certain structural and behavioural 
mTc-DISIDA (donated by Syncor International) was serially diluted to the required 

 Low radiation dose (YALLOW, 1981). 
 
A large number of 99mTc agents were developed for hepatobiliary scintigraphy. 
Amongst the most successful agents used were derivatives of N-substituted 
iminodiacetic acid or commonly known as Tc-HIDA. Tc-HIDA was found to clear 
the blood rapidly. The generic name for the 99mTc agent used in this study is disofenin 
(DISIDA) (HENKIN, 1996; HIBBARD, 1982). 
 
D
similarities to bilirubin. Bilirubin and DISIDA share a number of analogies with 
regard to hepatocellular uptake: 
 Transported in plasma bound to albumin, 
 Accelerated dissociation of their albumin complexes at the hepatocyte surface, 
 Uptake kinetics display features of carrier mediated transport. 
 
It is against this background that studies on 99mTc-DISIDA were carried out as 
opposed to bilirubin. Okuda’s research demonstrates that 99mTc-DISIDA appears to 
enter the liver principally over the bilirubin transport system (OKUDA, 1986). 
 
Preparation of 99mTc-DISIDA 
99
dose with cell culture medium (10% DMEM for HuH7 and 5% DMEM HepG2). The 
hepatobiliary agent was then ready for use in the in-vitro cellular uptake studies. 
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Hepatocytes were grown in 50 ml Nunc flasks to 100% confluency. Culture medium 
m ced with the radioactive medium. After 1 
n ium was removed and cells were washed 
to remove any radioactivity not trapped 
ithin the cells. Trypsin (1 ml) was added to the flask to remove the cells from the 
e 2.2.3.2.1 suggests that both the HuH-7 and 
ep teristics for 99mTc-DISIDA. 
 
 
 and 
e 
fro  the flasks containing cells was repla
mi ute of incubation, the radioactive med
with 3 ml phosphate buffered saline (PBS), 
w
flask surface. Cell culture medium (3 ml) was added to the flasks to inhibit the action 
of trypsin. 100 ml of cell suspension were sampled and sent for gamma counting. 
Cells were counted using a haemocytometer. Cell viability was assessed by Trypan 
Blue exclusion. Each data point was the result of three separate experiments. 
 
2.2.3.2. Results 
 
Cells were incubated in radioactive medium for the various time periods, after which 
the cellular uptake was determined. Figur
H G2 cell lines exhibit similar uptakes charac
 
 
 
 
 
 
 
 
Figure 2.2.3.2.1: Graph of uptake of 99mTc-DISIDA (cpm/106cells) by HuH-7
HepG2 as a function of tim
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Initial rates (rmax,o) of 99mTc-DISIDA were calculated from the slopes of the 
cumulative uptake curves during the first 60s of incubation as this was the steepest 
linear portion of the concentration/ time curve (indicating the maximum rate). Results 
were expressed as curies per 106cells per min as a function of the concentration of 
activity the cells were incubated in. 
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Figure 2.2.
tic Model 
or the computation of kinetic constants, values for 99mTc-DISIDA, rmax,o and 
oncentration of activity were fitted directly to the Hill equation (Refer to Equation 
.2.2.2.1), as was done for lignocaine. The following values were obtained by 
eration: 
lls/min Rmax, HepG2 = 4.50 x 10-8 Ci/106cells/min
3.2.3: Rate of uptake (Ci/ 106cells/min) of 99mTc-DISIDA by HepG2 Cells 
fitted to the Hill Kine
 
F
c
2
it
 
Rmax, HuH7 = 6.10 x 10-8 Ci/106ce
Km = 6.00 x 10-8 Ci/ml Km = 6.55 x 10-7 Ci/ml 
h= 0.8 h = 1.30 
 
Table 2.2.3.2.1: Values obtained for the Hill model variables for HuH-7 and HepG2 
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 Both hepatoma cells lines are able to remove the radioactive isotope from solution 
plying the same capability with respect to bilirubin removal. The mechanism of 
mTc-DISIDA hepatocellular uptake was not investigated in this study only the 
apability to remove it from the complete culture medium was studied. The maximum 
tes achievable by both cell lines are fairly similar with the maximum achievable 
te of HuH-7 appearing slightly higher. This once again illustrates very similar 
inetic behaviour demonstrated by the respective Rmax values, being of the same order 
f magnitude. 
8 min (for a normal liver cells) (HENKIN, 1996). In 
rder to compare measured reaction rates to the half life and hence to the reaction 
im
99
c
ra
ra
k
o
 
99mTc-DISIDA has a physical half-life (t½phys) of 6.04hr (i.e. decay rate) and a 
biological half-life (t½biol) of 18.
o
rates quoted in literature, we assumed that the uptake of 99mTc-DISIDA exhibits first 
order kinetics, where: 
A
A nkCxndCrate −==                                                                 Equation 2.2.3.2.1 dt
en the rate constant k is: th
n
2/1t
k 2Ln=                                                                                     
being t s. 
ssuming maximal removal rates calculated for HuH-7 (6.03x10-8 Ci/106cells/min) 
 
onstant (k) for both cells lines was computed and compared with the rate constant (k) 
for normal liver cells. 
Equation 2.2.2.2.2  
with n he number of cell
 
A
and HepG2 (4.48x10-8 Ci/106cells/min) at approximately 1x 10-5 Ci/ml, the rate
c
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  Normal Liver 
Cells 
(whole liver) 
Normal Liver 
Cells 
(106 cells) 
HuH-7  
(106 cells) 
HepG2 
(106 cells) 
Rate Constant 
(k) 
0.0369 min-1 1.609x10-8 min-1 0.0017 min-1 0.00255 min-1
Half Life (t1/2) 18.8 min ~ 4x107 min 399 min 271 min 
Table 2.2.3.2.2: Comparison of rate constants (k) and half-lives (t1/2) for normal liver 
cells and transformed liver cells (HuH-7 and HepG2). 
lume of 3l one can compute the plasma concentration to be 
1.67x10-6Ci/ml. 
 
 
Figure 2.2.3.2.4: Concentration range of 99mTc-DISIDA administered to patients 
superimposed on the HuH-7 rate curve. 
 
From the table above, it is evident that the immortalised cells lines once again 
outperform normal liver cells. 
 
99mTc-DISIDA is usually administered to patients as a bolus injection of 5mCi. 
Assuming a plasma vo
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 Results indicate t  f fo ious tw ed, the 
transformed hep s, HuH-7 epG2 hav lity to mTc-
DISIDA at a mu  than that which occurs in vivo [See Table 2.2.3.2.2]. 
 p icat sign rid r 
tor (HALR) in terms of the mass of cells required. Since this reaction was studied 
ty of b emova ood by  its anal
c carrier mediated removal). It 
 however interesting to note that these toxins are not life threatening as such. 
rubin. 
sising that the type of cell incorporated into our reactor is no larly 
ignificant
hat for this liver
atocyte
unction test as 
and H
r the prev o discuss
e the abi remove 99
ch faster rate
This could have
reac
ositive impl ions for the de  of our hyb artificial live
to test the abili ilirubin r l from the bl  studying ogue 99mTc-
DISIDA,we can assume that both the hepatoma cell lines are highly capable of 
removing toxins utilising the bilirubin pathway (anioni
is
Jaundice is only life threatening in babies, as their blood brain barrier is not 
completely impermeable to bili
 
Once more the data demonstrate that both cells lines have similar reaction kinetics 
over a wide range of concentrations or activities that the cells were incubated in, once 
more empha t particu
s  in the reactor design process. 
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2.3 DISCUSSION AND CONCLUSION  
 
The aim of this study was to determine the sensitivity of the reactor design to the cell 
line incorporated. The reaction rates measured for the transformed cell lines are of the 
same order of magnitude for each liver function tested. This implies that the reactor 
design is not significantly sensitive to which of the two cell lines is incorporated in 
the design of the HALR. Refer to Table 2.3.1 below for a summary of the results 
obtained.  
 
Transformed 
Cell Line 
Rmax Urea 
Metabolism 
Rmax for 
Lignocaine  
Rmax for 99mTc-
DISIDA 
 
HuH-7 2.91 x 10-5 
mmol/106cells/min 
0.222 
nmol/106cells/min 
6.03 x 10-8 
Ci/106cells/min 
HepG2 3.61 x 10-5 
mmol/106cells/min 
0.178 
nmol/106cells/min 
4.48 x 10-8 
Ci/106cells/min 
Table 2.3.1: Comparison between the maximum rates achievable for HuH-7 and 
HepG2 cell lines for selected liver biochemistries. 
 
The HuH-7 cell line appears to be a slightly better choice with respect to lignocaine 
nd DISIDA uptake, however marginally. The HepG2 cell line seems to metabolise 
urea at a slightly higher rate. The maximum rates achievable for ammonia 
metabolism and lignocaine uptake were compared to the rates at which normal liver 
cells perform these functions in-vivo to get an idea of the rate limiting reaction 
between the liver functions investigated. For both of these reactions, the maximum 
rates observed were higher than the average rates found in the literature for normal 
liver cells. This can be explained by referring back to the graphs, which illustrate the 
range of concentrations the reaction rates were measured for. It is quite interesting to 
discover that as one increases the concentrations of the various substrates to levels 
higher than those regarded as toxic in the human body, the cells seem to perform 
better.  
a
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For  third liver function test, the A uptake was studied as a bilirubin 
nalogue due to the difficulties encountered with accurate bilirubin determination. 
he cells have demonstrated that much higher rates than those quoted in literature are 
ld be explained by assuming the higher concentrations 
(related to the higher reaction rates measured) are not toxic to the cells themselves. 
uld imp ver failu  con uld be 
 to elevate, and re the ce  perfo  higher 
 is also possible that the liver has a tremendous amount of redundancy built into it. 
lirubinemia is not life threatening to an adult. High concentrations of 
bilirubin could be removed by other devices connected in series with an artificial 
99mTc-DISID
a
The half-life of 99mTc-DISIDA uptake for the two cell lines was compared to the in-
vivo half-life of 99mTc-DISIDA uptake. Results demonstrate that just as for the 
previous two liver function tests, the HuH-7 and HepG2 cell lines have similar 
reaction rates and significantly higher rate constants than that calculated for normal 
liver cells normalised to 106cells. 
 
T
achievable. These findings cou
This wo ly that during li re or injury, the centrations wo
expected  therefo lls are driven to rm at a much
rate.  
 
It
Therefore, at any one time, not all the hepatocytes are engaged in performing all the 
various reactions. Those involved in the various biochemical conversions at the 
prevalent substrate concentrations are not performing at their highest possible rate 
either. All of these findings make for interesting implications with respect to the 
design of the HALR. This would also explain the survival and normalcy of function 
in patients who have had a partial hepatectomy. 
 
If one had to choose a reaction to design for, based on reaction rates and the number 
of cells required, either ammonia metabolism or lignocaine uptake could be selected. 
This is as a result of the ability of the transformed cell lines to function at 
significantly higher rates than those quoted for normal cells functioning in-vivo. 
Hyperbi
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reactor, or by some other means (not within the scope of this study) and is therefore 
not the first choice reaction to design the reactor for.  
 
The next step in the design of an artificial liver reactor is to investigate what effect 
microencapsulating these cells would have on the mass transfer characteristics of the 
reactor and the design implications of those findings. 
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easured. The kinetics of external mass transfer were 
pared to the intrinsic cell kinetics previously measured to determine the rate-
iting step. Results indicate that the capsular membrane does not significantly 
pede mass transfer and that intrinsic cell kinetics is the rate-limiting step. This 
implies that the reaction rate will depend only on the quantity of cells incorporated in 
the reactor and not on membrane area, structure or size.  
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The aim of this study was to determine the membrane effects on mass transfer across 
microencapsulated hepatocytes and subsequently the implications of 
microencapsulation for the reactor design. Cell viability within the capsular 
environment was ascertained via α-fetoprotein production. Mass transfer data for 
substrates (urea, lignocaine) that would potentially cross the m
in a HALR scenario were m
com
lim
im
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3.1 INTRODUCTION 
 
Process synthesis methodology aims to advance technology through the application 
of market related concepts to process development. The paradigm shift that is taking 
in the scientific arena has resulted in the move from an isolated sequential 
ory 
nce of the designer. The process is then 
eveloped from the laboratory data in isolation from the laboratory personal. Instead, 
 a common occurrence, the 
hronic shortage of donor organs impels the need for the development of an 
xtracorporeal liver assist device, either as a bridge to transplantation or to provide 
prieve for a damaged liver to recover. 
place with
approach in the development of new processes and technologies to a more iterative, 
time, energy and financially efficient process. 
 
In the traditional sequential approach to developing a new process, laborat
measurements are often obtained in the abse
d
we have employed the iterative approach described by GLASSER, HILDEBRANDT 
& McGREGOR (1998). In this approach, the process is designed with whatever 
information, albeit limited, is available, and measurements are then obtained 
depending on which variables need optimising. 
 
The development and modelling of artificial organs, such as the liver, is one such area 
where engineering methodology, and in particular, process synthesis has seen wide 
applicability. Our focus is on developing and modelling bioartificial liver support. 
Despite recent advances in modern medical therapy, patients with fulminant hepatic 
failure (FHF) have a mortality rate approaching 90% (DIXIT & GITNICK, 1996). 
While technology has made human organ transplantation
c
e
re
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Laboratory experimentation included determining the liver functionality expressed by 
uH-7 and HepG2, aimed at assessing specific liver 
; NAGAKI et 
, 2000). Our own experimentation has demonstrated the capability of both cell lines 
Microencapsulation of cells 
ty so that the large antibodies are prevented 
om crossing the membrane thus circumventing the need for immunosuppression, 
while ensuring cell viability via bi-directional diffusion of nutrients, oxygen, 
metabolites and allowing their products unimpeded diffusion out. The capsular 
environment provides cells with cell-cell interaction (synergistic interactions between 
two hepatoma cell lines, namely, H
functionality, as well as the sensitivity of the reactor design to the cell line chosen. 
Research has demonstrated that both cell lines chosen exhibit a stable phenotypical 
expression of some differentiated liver functions in long term cell culture. Both these 
cells have been reported to produce a number of plasma proteins, liver specific 
enzymes and bile acids (NAKABAYASHI, 1984; MIYASHITA, 2000
al
for ureagenesis, P450 activity (drug metabolism) and bilirubin type functionality 
(Chapter 1). 
 
The aim of this study is to determine the membrane effects on mass transfer across 
microencapsulated hepatocytes and subsequently the implications of encapsulation 
for the reactor design. 
 
3.1.1  
 
Bioartificial liver support research harnesses the natural capabilities of liver cells by 
encapsulating them in a semipermeable membrane and incorporating them in 
bioreactors of various configurations (DIXIT & GITNICK, 1996). This encapsulation 
can be achieved in a number of ways, and in our research, the cells are protected from 
immune rejection by microencapsulating them in sodium alginate beads. 
Microencapsulation is based on the premise that cells, once sequestered within a 
semipermeable membrane, are isolated from the immune system and therefore cannot 
be recognised and destroyed by the host’s immune defence system. This is achieved 
by designing the membrane, permeabili
fr
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adjacent cells), which exist in-vivo, nutrient-product and pH gradients (Reddy, 2001; 
REID & JEFFERSON, 1984). Furthermore, the microencapsulation prevents the 
hepatoma cells away from infecting the patient. 
 
Microencapsulation of cells provides the advantage of obtaining high cell densities in 
the reactor as compared to cells in hollow Fibre devices (HFDs) or cells in free 
suspension. Hepatocyte isolation within a microcapsule allows the cells to organise 
themselves into three-dimensional structures. Wu et al. (1996) hypothesised that this 
organisation contributed to enhanced liver specific activity. The high cell loading 
leads to high volumetric productivities. It also enables the use of higher dilution rates, 
s there is no culture washout.  
in 1964. The development of artificial cells led to the 
icroencapsulation of biological materials becoming an area of study for industrial 
G & CHANG, 1991). Artificial cells 
ere first prepared as ultrathin polymer membranes of cellular dimensions, 
a
 
CHANG first reported artificial cells, prepared from microencapsulation of 
biologically active materials, 
m
purposes as well as biomedical research (WON
w
microencapsulating the proteins and enzymes extracted from biological cells (DIXIT 
& GITNICK, 1996). 
 
3.1.2 Kinetic Determination of Rate Limiting Step 
 
The reactor incorporating these encapsulated cells is modelled on data obtained in the 
laboratory, and reaction rates are fundamental to the design process. The overall 
reaction rate could be limited by intrinsic cell kinetics, mass transfer within the bead, 
diffusion across the membrane, or external mass transfer. The design process thus 
only requires laboratory tests that provide this information. This approach is 
advantageous as a better process is developed more rapidly as less time and money 
are spent on irrelevant experiments. 
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Laboratory experiments performed included cell encapsulation to ascertain cell 
viability within the capsular environment, demonstrated by α-fetoprotein (AFP) 
production, as well as mass transfer measurements for the semipermeable membrane. 
ass transfer data produced were compared with the intrinsic cell kinetics previously 
influence the reaction rate if diffusion across the 
embrane is rate limiting. If external mass transfer is determined to be rate limiting 
re 
e’s Medium DMEM (1.0 mM 
ficult to detach were placed at 37 C 
acilitate dispersal. 3ml of complete tissue culture medium were added and mixed 
by gently pipetting. Cells were now ready for use. 
M
determined (Chapter 1) to establish the rate-limiting step. 
 
If intrinsic cells kinetics limit the reaction rate, then the rate will depend only on the 
quantity of cells in the capsular beads and not on the membrane area, structure nor 
particle size. If experiments indicate that the internal mass transfer is rate limiting, 
then the overall reaction rate is strongly dependent on bead radius. Membrane 
structure and area will only 
m
then it would imply a badly designed reactor. In terms of process synthesis, this 
would be the best-case scenario, as the flow in the reactor could be redesigned to 
better facilitate mass transfer. 
3.2 Materials and Method  
 
Hepatocyte Cell Cultu
 
Hepatocytes were cultured in Dulbecco’s Modified Eagl
sodium pyruvate, 2 mM L-glutamine, 0.1 mM non-essential amino acids, 1250 µL 
penicillin/ streptomycin) supplemented with 5-10% fetal calf serum. (All chemicals 
purchased from Sterilab Services, Kempton Park, South Africa). Spent medium was 
replaced every four days. Cell cultures were incubated at 37oC in a 95% air and 5% 
CO2 atmosphere.1.0ml of trypsin (Sterilab Services, Kempton Park, South Africa) 
solution was added to the flask and cells observed under an inverted light microscope 
until cell layer was dispersed. Cells that were dif o
to f
 
53
Droplet Generation 
 
The droplet generator used for microencapsulation consists of 2 co-axially arranged 
jets: the central jet consists of a 26G stainless steel needle (Perfektum; Popper & 
Sons, Inc.,New Hyde Park, NY) through which the sample is extruded, within a 16G 
urrounding air jet through which air is passed. To prevent sample occlusion at the 
sion to assume the most favourable shape to reduce 
mass transfer resistance – a sphere (maximum surface area to volume ratio). 
s
end of the air jet, the tip of the sample jet is fabricated such, that the sample jet 
extends 0.5mm beyond the end of the air jet (See Figure 3.2.1 & 3.2.2 below). The 
droplet generator is so designed that the tip of the needle is subjected to a constant 
laminar airflow, which acts as an airknife. The syringe filled with cell suspension is 
mounted on a syringe pump, which is activated to incremently force drops of the 
solution to the tip of the needle, where the droplet is cut-off by the air stream and falls 
into the gelling solution where the absorption of cross-linking ions causes immediate 
gellation. The distance between the tip of the needle and gelling solution is set to 
allow the alginate cell suspen
 
 
 
Figure 3.2.1: Apparatus set-up for microencapsulation  
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Figure 3.2.2: Droplet needle assembly 
 
Microencapsulation 
 
The method used for encapsulation was based that described by CHANG (1992). The 
isolated hepatocytes were resuspended in medium, or in the case of mass transfer 
experiments, saline was used. The cell suspension or saline was then resuspended in 
4% sodium alginate (4.0% sodium alginate, 0.9% saline, 20mM fructose). The final 
working concentration of cells and sodium alginate was adjusted to obtain a working 
concentration of 20 x 106 cells/ml and 2.0% respectively. In the case of mass transfer 
xperiments, a final working concentration of 2% alginate was produced. 
A syringe (Becton Dickinson & Co; Rutherford, N.J.) was filled with the 2% alginate 
suspension, the sample then extruded with a syringe infusion pump (Harvard 
apparatus; Millis, Mass) set at 0.1ml/min through the 26-gauge needle of the droplet 
generator. The droplets were sheared off by the air jet flowing through the16 gauge 
needle at 2.5 l/min.  
 
The droplets formed were allowed to fall dropwise into a beaker containing 200ml of 
2 M CaCl2, 10mM HEPES, 
M fructose, pH 7.4), where they were allowed to gel for 15 minutes on contact 
with the CaCl2 solution.  
 
e
 
an ice cold, gently stirred 100mM CaCl  solution (100m
20m
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The alginate matrix on the surface of the microcapsule was stabilised with poly-L-
lysine by immersion in 80ml of a 50 mg% solution of poly-L-lysine (50 mg% poly-L-
lysine, 0.9% NaCl, 10mM HEPES, 20mM fructose, pH 7.4) for 20 minutes. 
 
The microcapsules were then drained, washed with buffered saline and immersed in 
200ml of 0.1% sodium alginate (0.1% sodium alginate, 0.9% NaCl, 10mM HEPES, 
 apply an external layer of alginate. 
ere collected and immersed in 200ml of 50mM sodium citrate 
0mM sodium citrate, 0.8% NaCl, 20mM fructose, pH 7.4) for 6 minutes to 
 prior to 
ined via trypan blue exclusion. All apparatus to be used in 
0
20mM fructose, pH 7.4) for 5 minutes to
 
The microcapsules w
(5
solubilise the intracapsular calcium alginate. 
 
The resulting microcapsules were then washed with saline and ready for use. 
 
Determination of Encapsulated Hepatocyte Viability 
 
HuH-7 cells were cultured in the manner described above and viability
encapsulation was determ
the microencapsulation procedure was sterilised by autoclaving at 200 C for an hour. 
Cells (1 x 107cells/ml) were microencapsulated as per method described above and 
incubated in complete culture medium at 370C in a 95% air and 5% CO2 atmosphere. 
Daily samples of the medium were analysed for AFP. 
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Mass Transfer Across the Capsular Membrane 
 
Empty microcapsules were prepared with saline suspended in 4% sodium alginate to 
roduce a working concentration of 2% as per method described above. The 
intervals 
hile attempting not to remove any microcapsules. These samples were added to 
.14855.0001) for urea. 
p
microcapsules were then added to solutions of lignocaine (7nmol/ml in saline) and 
urea (20mmol/l in saline) respectively which were being gently stirred on a magnetic 
stirrer. Aliquots of the supernatant liquor were sampled at particular time 
w
eppendorf vials equipped with 0.45 µm filters and centrifuged (10oC, 3000rpm, 
5minutes) to remove any capsular debris and analysed via HPLC for lignocaine and 
UV-VIS Spectrometer at 340nm using the Merck Ecoline 25 ® Urea Kit 
(1
 
3.3 RESULTS 
 
Encapsulated Hepatocyte Viability 
 
 
Figure 3.3.1: Photograph showing HuH-7 cells in an alginate-polylysine-alginate 
(APA) microcapsule on Day 7. 
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 Time Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 
Concentration  
ng/ml 
1.8 277.56 289.68 293.64 297.36 297.6 308.16 
 
Table 3.3.1: AFP production by encapsulated HuH-7 cells (2.5 x 107cells initially on 
Day 0) over a period of six days. 
 
Results demonstrate that encapsulating the hepatoma cells does not affect their 
viability as is indicated by the production of AFP for up to six consecutive days. 
Capsules containing cells were ruptured daily and viability assessed by trypan blue 
exclusion. Cell viability according to trypan blue exclusion had decreased by day six 
y approximately 10%. 
hus, in designing an artificial liver, one could expect cells to remain viable for at 
of these findings for clinical application are 
articularly promising. Firstly, if one had to be guided by kidney dialysis, 
microcapsules containing cells do not need to be replaced during a therapeutic 
perfusion session. Secondly, cartridges or reactors can be prepared in advance. 
 
 
b
 
T
least six days. The implications 
p
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 Mass Transfer Ac  C  M e ross the apsular embran
 
 
 
igure 3.3.2: Empty microcapsules suspended in phosphate buffered saline (PBS) for 
 
 
 
 
 
Figure 3.3.3: Lignocaine concentrations in bulk solution containing empty 
microcapsules measured as a function of time 
 
F
use in mass transfer experiments 
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Figure 3.3.4: Urea concentrations in bulk solution containing empty microcapsules 
measured as a function of time 
 
If we assume that the diffusion of lignocaine and urea across the capsular membrane 
icrocapsule tends to zero, then the half-life of 
iffusion is calculated using: 
follows first order kinetics i.e. the mass transfer coefficient is approximately constant 
and the concentration within the m
d
 
)( mequilibriuCCkdT
dC −                                                                      −= Equation 3.3.1 
a straight-line equation, where k is the slope of the line: Integrating both sides yields 
)()( )0()( mequilibriutmequilibriut CCLnktCCLn −+=− =                                    Equation 3.3.2 
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Where: 
dT
dC   
   mass transfer co-effecient, 
 substrate concentration in the bulk solution; 
 the concentration reached at equilibrium 
½  half-life or time at which C= C0/2 
 order to establish whether intrinsic cell kinetics or external mass transfer is the 
 and 3.3 we were able to establish the transport half 
ves for diffusion of urea and lignocaine across the capsular membrane. 
 
 
 
 
Figure 3.3.5: Determination of t ½ for lignocaine from the linearisation of the rate 
equation 
change in concentration as a function of time, 
k
C  
C mequilibriu
t 
 
In
rate-limiting step, the half-lives (t½) of both reactions will have to be calculated and 
compared. Using equations 3.2
li
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learly, neither of the two systems appears to be well approximated by the first order 
ystem. However, as
tted the data to a straight line, as illustrated by the graphs Figure 3.3.5 and 3.3.6, and 
omputed the following half lives for mass transfer across the microcapsule 
embrane: 
 lignocaine = 1.94 minutes 
½ urea = 0.76 minutes 
 similar calculation can be done to calculate the intrinsic cell kinetics of 
ing the same initial concentrations of 
both substrates as was used in the experiment above, fabricating the same number of 
beads except that this time they contain hepatocytes and maintaining the cell loading 
(cells per bead) derived from the concentration of cells (20 x 106cells/ ml) suggested 
by CHANG’s patent (1992). 
 
 
 
 
 
Figure 3.3.6: Determination of t ½ for urea from the linearisation of the rate equation 
 
C
s  we are only interested in order of magnitude results, we have 
fi
c
m
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A
encapsulated cells for the exact same experimental conditions as the mass transfer 
experiments described above. These include us
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As our inte ass transfer 
cross the capsular membrane is the rate limiting reaction - therefore the reaction the 
esigner would have to design the reactor for, an order of magnitude calculation will 
uffice to reach this conclusion. For this reason, we did not measure the functionality 
f encapsulated cells and made the assumption that the rate determined for 
nencapsulated cells would be similar to that of encapsulated cells. Other researchers 
ave conducted these studies and have concluded that microencapsulating 
epatocytes does not alter the functionality of the cells (CHANG, 1992, 2001; 
ANAPLE, 2001; HAMAZAKI, 2002). 
 the mass transfer experiments), and 1800 microcapsules (the number of capsules 
rest is in establishing which of intrinsic cell kinetics or m
a
d
s
o
u
h
h
C
 
Using an initial bulk concentration of 7nmol/ml of lignocaine (the concentration used 
in
formed using 5ml of 2% cell/ alginate suspension), with a cell concentration of 20 x 
106cells/ml and a maximal rate of uptake by hepatoma cells of lignocaine (Chapter 1), 
Rmax = 0.1778 nmol/ 106cells/min2, t½lignocaine for the cells can be computed: 
 
max
)0(
2
1
5.0 Ct = Rt=                                                                               Equation 3.3.4 
in 
imilarly for urea, using C (t=0) = 18 mmol/l (the concentration used in the mass 
-5 6
                                              
t½ lignocaine (encap. cells) = 3.9m
 
S
transfer experiments), and Rmax = 2.91x10  mmol/ 10 cells/min (Chapter 1), the half-
life of ammonia metabolism is calculated using Equation 3.3.4, yielding: 
t½ urea (encap. cells) = 30.92 min 
 
   
aximal rate of HepG2 was used as it was the lower maximum rate reached between HuH7 and 
HepG2. 
2 The m
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The half-life computed for mass transfer and intrinsic cell kinetis for urea differed by 
a factor of ten. For lignocaine, the values calculated were of the same order of 
magnitude. The values computed for the half-life of the intrinsic cell kinetics was 
based on the maximum rate achievable by these cells. This implies that the scenario 
modelled would be the worst case, yet the half-life of mass transfer across the 
membrane is faster, indicating that mass transfer is not rate limiting even when 
compared to the half-life of cell kinetics at the highest reaction rates. For a real case 
scenario, the reaction rates achievable would depend on the maximum concentration 
of the substrate in blood and further more the half-life would also depend on the cell 
ading of the microcapsules. As the reactor will most probably not be operating at 
 
 
lo
maximum rate, the real situation would be one where mass transfer has a far shorter 
half-life than intrinsic cell kinetics (a much higher differential then obtained in these 
calculations).  
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3.4 DISCUSSION AND CONCLUSION 
 
This drop method employed to form the microcapsules results in alginate-polylysine-
alginate (APA) microcapsules containing cells. The formation of non-spherical 
microcapsules was eliminated by adjusting the height of the needle assembly from the 
surface of the CaCl2 solution to greater than 20cm. We used a clearance height of 
approximately 30cm. As the rate of the air inflow increases, the size of the 
microcapsules decreases. An air infusion rate of 2l/min produced microcapsules of a 
diameter of 800µm + 100µm. 
 
Capsule diameter is a very important property. The capsule must be sufficiently large 
to contain the cells.
washing and settling or in reactor operations
 Larger capsules are preferable as they are easier to handle during 
 such as fluidisation. The probability of 
 in the microcapsule is therefore related to Poisson’s Law. To ensure at 
ean cell number per capsule must be higher than four. 
at are too large suffer the problem of limitations to mass transfer created 
by an internal dead volume. Therefore, we chose to keep our bead diameter as small 
as possible. 
 
There have been many modifications made to the original encapsulation by 
researchers (DORIAN, R.E., 1995; GOOSEN, M.F.A., 1987; SOON-SHIONG, 1998; 
CHANDY, 1999) to increase hepatocyte viability and functionality for transplanted 
microcapsules, as well as to better control the permeability properties and uniformity 
of the membrane (GOOSEN, 1985; TSANG, 1987). DIXIT’s study (1992) showed 
that Matrigel could significantly enhance hepatocyte function when used for 
microencapsulation. MIURA and co-workers (1986) demonstrated that hepatocytes 
within calcium alginate showed liver specific characteristics, and these activities were 
almost comparable with those of monolayer-cultured cells.  
finding cells
least one cell per capsule, the m
 
Capsules th
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The concept of an artificial liver based on microencapsulated hepatocytes has been 
. Functions of the encapsulated 
was maintained for long periods in vitro and in 
 (WONG, 1988; CAI, 1989). These hepatocytes also release a hepatotrophic 
ithin the artificial cells (LANDRY, 1985). BENOIST, et al. 
 
morphologically distinguishable forms of hepatocyte structures in 
icrocapsules. The tendency to form spheroids in microcapsules increased when high 
validated by this and others’ previous studies
hepatocytes were the focus of many a study (CHANG, 1992, 2001; CANAPLE, 
2001, HAMAZAKI, 2002). Our own studies indicate that cells can be kept alive and 
functional for up to six days. It most probably is longer but laboratory experiments 
were only conducted for a period of 6 days. Intraperitoneal implanted encapsulated 
hepatocytes prolonged the survival time of galactosamine-induced FHF in rats 
(WONG; 1986); as well as lowered the bilirubin level in Gunn rats (BRUNI, 1989, 
1991; DIXIT, 1990). Their viability 
vivo
factor that is retained w
(2001) demonstrated the survival and functionality of porcine hepatocytes 
transplanted in large quantities in the peritoneal cavity of allogeneic animals 
following semiautomatic encapsulation. 
 
Very little is known of the structure of hepatocytes in the microcapsules. A proper
three-dimensional cytoarchitecture is important for hepatocytes to maintain 
differentiated functions. It is important that the correlation between the structure of 
the encapsulated hepatocytes and their viability be investigated. ITO and co-workers 
(1992) have shown 
m
molecular weight poly-L-lysine was used to form the microcapsular membrane. 
Protein-producing ability of hepatocytes is exerted more in the spheroid culture than 
in the monolayer culture. Once spheroids were formed in microcapsules, the viability 
and protein-producing ability were maintained for at least 30 days (ITO, 1992). 
 
 
66
Our own data demonstrate that encapsulated hepatocytes are able to maintain their 
viability for up to six days. Mass transfer data indicate that for the capsules we 
fabricated the presence of the capsular membrane does not hinder mass transfer to 
and away from the cells. Work by BRUNI & CHANG (1995) has demonstrated that 
both free and microencapsulated hepatocytes were equally effective in lowering the 
serum bilirubin thus validating our results that the capsular membrane does not affect 
the efficacy of encapsulated cells. Mass transfer experiments were conducted for urea 
and lignocaine only due to the availability of 99mTc-DISIDA (source - generous 
donation). Urea would be a representative of small molecules and lignocaine of larger 
molecules that would have to cross the membrane. Results are summarised in the 
table below: 
 
Substrate of Interest t½ Membrane Mass 
Transfer 
t½ Cellular Uptake 
Lignocaine 1.94 minutes 3.9 minutes 
Urea 0.76 minutes 30.92 minutes 
 
Table 3.4.1 Comparison of the half-life of mass transfer across the microcapsule 
membrane with the half-life of cellular uptake for the two substances of interest. 
 
The intrinsic cell kinetics for ammonia metabolism to urea is a factor of two slower 
than the diffusion rate across the membrane. Since the reaction rates used for 
comparison were based on the maximum rates (rmax) achievable, this reflects the best-
case scenario. In clinical application, the reaction rates will most probably be much 
lower than the rmax depending on the concentration in blood that requires removal, 
us implying that the half-life of intrinsic cell kinetics will be much slower than the 
diffusional rates. 
 
th
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Thus, we can conclude that mass transfer across the capsular membrane is not rate 
limiting. Hence, the membrane does not require optimisation for improved mass 
transfer across it. Intrinsic cells kinetics rather than mass transfer limits us. Hence as 
we do not believe that we can affect intrinsic cell reaction rates we have the best-case 
scenario as far as reactor design is concerned. The reactor design would thus depend 
mainly on the number of cells we can incorporate into into a given volume as the 
reaction rate is limiting. This simplifies the choice of reactor type and design of 
reactor. 
 
From these simple relatively inexpensive laboratory experiments we can illustrate the 
following: 
 Membrane structure does not significantly impede the flow of substrates or 
he caps ared to the cell reaction rate. 
 The rate-limiting step w ined to be the intrinsic cell kinetics, which 
be enhanced. 
ptimisable parameters sule size and the number of microcapsules 
incorporated in the final reactor design, in order to match cellular uptake rate to 
able 
reaction rates. 
products across t ular membrane comp
as determ
cannot 
 O are microcap
membrane transfer rate. 
 The cell loading i.e. cells per bead could be increased to increase the achiev
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4. 
 
A FEAS SIGN OF A HYBRID 
ARTIFICIAL LIVER REACTOR 
 
 
This chapt n. Parts of this paper 
were presented at the PSE2004 Conference held in China in January 2004.  
 
 
CHAPTER THREE 
IBILITY STUDY FOR THE DE
er was written in the form of a paper for publicatio
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A FEASIBILITY STUDY FOR THE DESIGN OF A HYBRID ARTIFICIAL 
ACTOR (HALR) LIVER RE
 
T. Vally1, D. Hildebrandt , D. Rubin , D. Glasser  and N.J. Crowther1 2 1 3  
esis, School of Process and Materials 
Information Engineering,  
ent of Chemical Pathology, National Health Laboratory Service, Faculty of 
Health Sciences,  
oss of more than 60% of liver function can become very detrimental to a patient’s 
ealth and consequently life. Liver failure results in the loss of maintenance of a 
normal metabolic balance. This causes a build-up of toxins in the body, which may 
subsequently lead to secondary organ failure, as the liver is no longer producing 
important nutrients. To date, there is not a single therapeutic device capable of 
prolonging a patient’s life until the diseased or injured liver recovers or is able to 
bridge a patient to liver transplantation. Various hybrid artificial liver systems have 
been researched, tested and proposed as possible therapeutic modalities. They include 
the use of hollow fibre devices in their various configurations, the use of non-woven 
fabric encased in a plastic cartridge and the use of encapsulated hepatocytes in 
fluidised bed reactors. We propose the use of a packed bed reactor incorporating 
microencapsulated hepatocytes perfused by heparin anticoagulated arterial blood. 
This configuration circumvents the need for immunosuppression, plasmapheresis, as 
well as in vitro ventilation while at the same time overcomes the limitations of low 
mass transfer properties and cell volume design constraints. Furthermore it provides a 
uniform microenvironment as well as ease of scale up. Previous work (Chapter 1 and 
2) determined that intrinsic cell kinetics were rate limiting and that 
microencapsulating hepatocytes does not significantly impede mass transfer when 
compared to intrinsic cellular kinetics. The aim of this study was together with data 
obtained in the laboratory to design and assess the feasibility of a reactor for use as a 
bioartartificial liver reactor. 
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4.1 INTRODUCTION 
 
If one were to imagine the body as a chemical processing plant, then the liver would 
 hardly any chemical produced, secreted or regulated that the liver is 
y researcher. It is currently impossible to replicate the multitude 
f the 21st century. 
be equated with the reactor responsible for almost all the metabolic activities of the 
body. There is
not directly or indirectly responsible for, making the design of an artificial liver a 
daunting task for an
of functions of a single liver cell, even given all the knowledge and technological 
advances o
 
The first step in designing the reactor is ascertaining the actual or effective reaction 
rate. This is primarily determined by the intrinsic cell kinetics of the cells to be 
incorporated. The preferred method chosen to incorporate cells into the reactor is via 
sequestration within a semipermeable membrane. The next step is determining what 
the rate-limiting step in the process is. Intrinsic cell kinetics, mass transfer within the 
bead, diffusion across the membrane, or external mass transfer could limit the overall 
reaction rate. Intrinsic cells kinetics depends only on the quantity of cells in the 
capsular beads and not on the membrane area, structure or particle size. Internal mass 
transfer is strongly dependent on bead radius. Membrane structure and area will only 
influence the reaction rate if diffusion across the membrane is rate limiting. If for 
instance external mass transfer is determined to be rate limiting, as is the case with 
most hollow Fibre devices (HFDs) and plate dialyser models, then it would imply a 
reactor that could in principle be improved. If this were the case, it would allow the 
designer to improve the reactor or redesign it such that flow in the reactor could better 
facilitate mass transfer. Once the situation is achieved where the intrinsic cell kinetics 
is the rate controlling mechanism, no further improvements in this regard are 
possible. 
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The most critical issue in terms of reactor design is mass transfer resistance, i.e. mass 
ansfer to the membrane surface (controlled by design) and mass transfer across the 
s device is critical- as the less blood required to prime the device the less 
strain is placed on the already struggling patient. 
tr
membrane. Each hepatocyte in the intact liver functions under conditions of perfusion 
and close blood contact. Most bioreactor designs currently under investigation do not 
duplicate these conditions, which are essential for optimum substrate and metabolic 
exchange between the hepatocytes and media. Consequently, non-physiological 
gradients will occur which impair the metabolic activity of the cultured cells. 
Therefore, optimal mass transfer is an important aspect that should be addressed 
when developing a HALR. 
 
In order to determine which of the aforementioned processes was rate limiting, an 
initial study of hepatocyte intrinsic cell kinetics was undertaken. The functionality of 
two cell lines, HuH-7 and HepG2, was assessed for ureagenesis, P450 activity and 
bilirubin type uptake activity (Chapter 1). Laboratory results indicated the capability 
of both cell lines for all three functions and comparable intrinsic cell kinetics for both 
cell lines were exhibited. Laboratory data also indicate that both the transformed 
hepatoma cell lines were capable of significantly higher maximum rates of reaction 
than those quoted in the various literature sources for normal liver cells. 
 
Further work (Chapter 2) demonstrated that mass transfer across the microcapsule, 
was not significantly hindered by the membrane and therefore not the rate limiting 
reaction.  
 
The second critical issue involves the reactor volume constraints, i.e the number of 
cells that can be incorporated in to a given volume. This is important as this 
determines the intrinsic reaction ability of the reactor to process blood. Clearly the 
size of thi
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4.1.1  Review of Some of the Bioartificial Liver (BAL) Devices 
 
4.1.1.1. Hollow Fibre Devices 
The most researched reactor configuration is the hollow fibre device (HFD). Hollow 
fibre devices are reactors, which allow the isolation of cellular material from the bulk 
medium by means of hollow membranes (Refer to figure 1.1.1.1). The reactor 
configuration is conceptually equivalent to that of the shell and tube heat exchanger. 
Cells are cultured in either the lumen of the hollow fibre device , analogous to the 
tube of the heat exchanger, or in the extra capillary space (ECS), analogous to the 
hell, and the medium pumped through the cell deficient compartment.  
 the exterior surface of the capillary hollow s, which are bundled together 
ithin an enclosing plastic shell. Nutrient medium or blood is circulated within the 
s
 
 
 
 
 
 
 
 
Blood  
Out
Blood 
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Figure 4.1.1.1.1: Schematic of a capillary hollow fibre device. Hepatoma cells are 
cultured on
Cells 
Blood
Flow 
Capillary 
Hollow s 
ECS out ECS in
w
capillaries (Adapted from DIXIT,1996). 
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Research with this particular device began with the idea of WOLF & MUNKELD 
976), which was subsequently carried forward by SUSSMAN et al. (1992, 1996). 
tion of perfused hollow fibres with malignant 
he separation 
f porcine hepatocytes for use in the extracorporeal bioreactor (JAUREGUI, 1999). 
ussman’s Extracorporeal Liver evice (ELAD) 
ussman’s extracorporeal liver assist device (ELAD®) is being developed by a 
rivate co in the  States called VitaGen, Incorporated. The ELAD® is 
ased o ollow fibre device with C3A cells (cell line originating from a well-
ifferentiated hepatoblastoma, HepG2) in ted in the ECS. During treatment, the 
LAD® will be connected to a continuous haemodialysis machine which separates 
e cells from plasma which is then perfused through the ICS of the ELAD® 
(1
The first HFD consisted of a combina
rat hepatocytes. Cerra and co-workers modified the device by introducing the cells 
into the lumen of the hollow fibres i.e. intracapillary space (ICS). Gerlach in 
Germany created a three dimensional arrangement of three different classes of hollow 
Fibres that supported nutrition, oxygenation and blood transfer to 2.5 x 109 porcine 
hepatocytes (SHEIL, 2002). This device is labour intensive and expensive, which 
makes prolonged successful support unlikely. Demetriou and collaborators managed 
to treat some patients with his plasmapheresis circuit, which included t
o
 
S  Assist D
 
S
p mpany  United
b n a h
d ocula
E
th
(SUSSMAN, 1992&1996). VitaGen is involved in FDA approved clinical trials to 
evaluate the safety and efficiency of this device in patients with FHF while bridging 
them to liver transplantation (VitaGen, 2002). 
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All HFDs are restricted because of their inherently low mass transfer properties 
across a limited capillary membrane surface. HFDs are also subject to design 
constraints, which limit the volume of cells that can be incorporated in the device. In 
addition to these, even though most BAL systems utilise a filtering membrane to 
isolate bioreactor cells from the patient’s blood, micro-breakage of the filter may 
occur. 
 
Unequal distribution of cells in the network is possible, which could result in a 
decrease in nutrient diffusion to the cells. Establishing hepatocyte cultures in a HFD 
is not easy, due to the specific geometry of the device and the nature of hepatocytes 
as anchorage dependent cells. Hepatocytes introduced into the HFD tend to drop by 
ravity onto the bottom of the device shell. Researchers have used various attachment 
9) but prolongation of the 
ttachment process negatively influences the metabolic function of hepatocytes and 
lendrig’s approach to the BAL has been to devise a bioreactor that does not include 
hollow fibre membranes for blood or plasma perfusion. The device comprises a three-
dimensional non-woven polyester fabric for high-density hepatocyte culture as small 
aggregates and an integral oxygenator for on-site oxygenation of the cells. A scaled 
up 400 ml version of the bioreactor can hold up to 20x109 porcine hepatocytes 
(FLENDRIG, et al., 1997,1998,19995,19996). This configuration is purported to 
mimic the in vivo environment of liver cells. If this device is to attain clinical 
g
processes to anchor cells in a HFD (KARLIK, 199
a
consequently the bioreactor performance. 
 
It is very likely that non-physiological gradients will occur which impairs the 
metabolic activity of the cultured cells. In this respect, semipermeable hollow- 
membranes seem to be more a burden than a solution to the problem. The membranes 
can foul and act as a diffusional barrier. 
 
4.1.1.2. Flendrig’s Bioartificial Device 
 
F
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application, then concerns such as the potential risk of porcine endogenous retrovirus 
(PERV) infection and the possibility of emergence of virulent agents must be 
addressed for purposes of medical safety as PERVs have been shown to be capable of 
infecting human cells in vitro (SHEIL, 2002).  
 
The non-woven fabric (NWF) module approach has also been adopted by a Japanese 
search group. SAKAI & NARUSI (1998) have developed a bioartificial liver 
e (quoted above) whereas our reactor 
corporates 4.58x1011 hepatocytes in a 409ml reactor volume. 
hepatocyte monolayer cultures are placed in 
 configuration such that blood flows over the opposite surface of the membrane on 
apanese group has reported 
conclusive in vitro data using this system (DIXIT & GITNICK, 1996). Our reactor 
re
module which is filled with hepatocytes immobilised on non-woven polyester fabric. 
Apparently, the cell density in the module is comparable to a packed bed type 
bioreactor. The module is a spin filter-type perfusion bioreactor immobilising 2% 
number of human liver cells within a 150 ml volume. 
 
The reactor configuration we chose incorporates a higher number of cells per volume 
of reactor. To compare, Flendrig’s reactor configuration immobilises 20x109 porcine 
hepatocytes in a 400 ml reactor volum
in
 
4.1.1.3. Plate Dialysers 
 
Multiple membranous plates of primary 
a
which hepatocyte monolayers are cultured. One J
in
configuration is able to contain more cells. Further, this configuration would impede 
mass transfer to the membrane and perhaps across it. 
 
4.1.1.4. Hepatocyte Haemoperfusion 
 
DIXIT & GITNICK (1996) chose to pursue the path of incorporating 
microencapsulated hepatocytes in an extracorporeal chamber. The plastic chamber is 
composed of biocompatible polycarbonate, closed at both ends, except for blood 
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access via two external ports at either end. Results report improved survival time of 
animals with FHF and no significant adverse effects on the animal’s heamodynamics. 
 
4.1.2 Approach to the Reactor Desig
 
n 
aving reviewed all the literature on the various reactor configurations, it was 
when packed into the 
actor. 
igure 4.1.2.1: Schematic comparison between the cell loading in a packed bed 
H
obvious that the best possible route to pursue would be a reactor configuration that 
faciliated good mass transfer and allowed the most number of cells to be 
incorporated. This left two choices, the first being the membrane hollow fibre 
configuration actively being researched by many other research groups and the 
second being either the fluidised or packed bed reactor containing microencapsulated 
hepatocytes. 
 
The HFD approach was not investigated for all the inherent disadvantages mentioned 
in section 4.1.1.1. Furthermore, if one pictures the arrangement of cells with in the 
capillaries of a HFD and compares it to the spheres within a fluidised/ packed bed 
reactor, then it is obvious that the spheres contain more cells 
re
 
 
 
 
 
 
 
Hollow 
Fibre Device Higher number of 
cells in packed 
bed reactor  
 
F
reactor containing microencapsulated hepatocytes and a capillary HFD. 
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Furthermore, microencapsulation, based on CHANG’S (1992) method was chosen as 
it prevents immunological responses from the patient’s blood. A spherical 
microcapsule membrane has the greatest surface area to volume ratio then any other 
 thus ma across the microcapsule membrane 
eactor, was the best route to pursue. Both fluidised and packed bed 
actors allow direct perfusion of blood over microencapsulated hepatocytes. 
nd cold. A fluidised bed is therefore very suitable for biological systems 
quiring close temperature control (DAVIDSON, 1985). There is also a high rate of 
eat transf y 
e following features: 
 Low pressure drop across the bed (low ∆P); 
 No dead volumes; 
 Low shear; 
 Low cell number per vo THMER, 1956). 
shape, ximum nutrient/product exchange 
may be achieved. It is also postulated that the capsular environment allows better 
cell-to-cell communication thereby enabling cells to retain their functionality for 
extended periods (DIXIT & GITNICK, 1996). Spherical microcapsules offer better 
three-dimensional stability with respect to mechanical stresses.  
 
The next step was to determine which reactor configuration i.e. fluidised bed or 
packed bed r
re
 
Fluidised bed reactors have the properties of a liquid. One of the properties is 
excellent heat transfer. The same temperature is quickly established through out the 
fluidised system because the general agitation of the particles disperses local regions 
of hot a
re
h er to the beads in the bed. Fluidised bed reactors are also characterised b
th
 



lume of beads (O
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Packed bed reactors don’t have freeboard and therefore can accommodate a higher 
number of cells per volume of reactor. They are characterised by: 
 
 Higher-pressure drop across the bed (high ∆P); 
 High velocities could result in high shear forces; 
 High ∆P could result in high shear forces.  
 
To summarise: 
PROPERTY FLUIDISED BED PACKED BED 
External Mass Transfer Good  Less Good 
Pressure Drop Low High 
Shear on Bead Low High 
Dead Volumes Low Likely 
Cell Density Low High 
Table 4.1.2.1: Comparison of the physical properties between Fluidised and Packed 
Bed Reactors  
 
Both these reactor configurations will be investigated. 
 
4.2  REACTOR DESIGN 
 
We have adopted a Process Synthesis approach to the theoretical design of our 
bioartificial reacto ploying chemical engineering principles to the design 
process. In order to apply the Process Synthesis methodology, one needs to be able to 
eters of the reactor so that in the end one is able to do a 
imulation. Using this approach to Process Synthesis, we have 
advocated, we will use simplified calculations to test the feasibility of the reactor 
design. 
 
r by em
specify the important param
more rigorous Process S
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4.2.1 Introduction 
 
Ureagenesis functionality is very important as accumulation of ammonia can lead to 
m oratory appeared to perform this 
tion rates for the two hepatoma 
an those quoted for normal liver cells 
 the literature. Therefore, in terms of the reactor design, we can ignore this reaction. 
Bilirub  was meas anner by take 
demonstrated r studies (OKUDA, 1986) to use the 
thway. From those resul etic data for bilirubin c tion were 
oactive bilirubin analogu 99mTc-DISIDA was studie  
ent the accuracy prob associated with measuring bilirubin 
 under laboratory conditions. Bilirubin is life threatening in an infant, as 
 an adult, an increase in bilirubin concentrations is not life 
 
e reactor design.  
 
ll lines mentioned previously was determined by 
easuring the uptake kinetics of lignocaine by these cells. The functions of the P450 
at the rate limiting step, at least with respect to these two reactions, is the 
s themselves. This implies therefore that the measured rates of reaction 
co a then death. The hepatocytes tested in our lab
function more than adequately and the maximum reac
cell lines measured were significantly higher th
in
 
in conjugation ured in an indirect m  studying the up
kinetics of an analogue by othe
same anionic pa ts, kin onjuga
inferred. A radi e, d instead as this
would circumv lems 
concentration
the blood brain barrier has not developed sufficiently to prevent the bilirubin from 
crossing over. In
threatening as such and can be treated by various other means such as exchange
transfusion and exposure to UV light. Therefore, this reaction can also be ignored for 
th
The P450 activity of the two ce
m
system, which if decompensated is life threatening. Therefore this reaction would be 
a good choice as the primary basis for the design of the reactor. 
 
Laboratory work described previously in Chapter Two demonstrated that 
encapsulation of the hepatoma cells in beads does not result in cell reactions being 
mass transfer limited with respect to both lignocaine and urea. Thus we were able to 
conclude th
cell reaction
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obtained for the non-encapsulated cells can be employed for design purposes. 
urthermore, we were also able to demonstrate that encapsulated cells could be kept 
.2.2 Reactor Specific Rates 
 to a maximum value at high concentrations of the metabolite (or 
ubstance requiring removal). The high concentrations of these metabolites do not 
he data tabled below were obtained from various literature sources for normal liver 
F
alive for at least six days with only a small drop in activity. This implies that the 
essential metabolites could be supplied to the cells at the required rates. 
Microencapsulation therefore represents a powerful method for isolating the 
hepatoma cells from the whole blood. 
 
4
 
The variation in reaction rates has a direct impact on the reactor design. In order to 
obtain the required removal rates in the reactor, a certain number of cells has to be 
incorporated to effect this removal rate. The important question is what that number 
of cells is? 
 
4.2.2.1 Estimate of the Number of Cells 
 
The measured removal rates as a function of composition for all the reactions studied 
were given by an S-shaped curve, with a rapid increase in reaction rate at low 
concentrations rising
s
appear to impede the functioning of the cells, so that in all likelihood the toxicity 
levels will be set by the sensitivity of other organs to these materials. Thus, the 
hepatoma cells would have no difficulty in functioning at these high concentrations. 
 
T
cells. In table 4.2.2.1 reaction rates from the literature (column 1) were normalised for 
106cells and expressed in the units (column 2) that data measured in our laboratory 
were expressed, allowing easier comparison between normal liver cells and the 
transformed hepatoma cell lines. 
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 1Production/ Removal 
Rates 
(In units quoted in literature) 
Production/ Removal 
Rates 
(Converted to uniform 
units) 
Concentration 
in Blood 
(To be removed) 
Ammonia 2.08 x 10-9 mol/106cells/min 2.08 x 10-9 mol/106cells/min 100 x 10-6 mol/ l 
Lignocaine 23 x 10-3g/min 4.53 x 10-12 mol/106cells/min 1.73 x 10 –5 mol/ l 
Bilirubin 2250 – 350 mg/day 
3.3.088 x 10-13 
mol/106cells/min 
17.1 x 10 –6 mol/ l 
1 Production rate for urea from ammonia (YOON et al., 1999; ZUCKER et al., 1995), removal rates 
r lignocaine (HARDMAN, 2001; KATZUNG, 2001) and bilirubin (HAWKER, 1993). 
ns of the substrates in blood obtained from various literature sources. 
, we are not in a position to accomplish a 
ll design. The best we can do under the circumstances is to note that at the normal 
s 
 be designed for is 240g (LIU, 2002). To mimic as closely as possible the in-vivo 
dialysis units are in the range 100-200 mmHg. For 
e purposes of this design, an upper limit of 100 mmHg is set. 
fo
2.Assume this is the clearance rate for entire mass of hepatocytes =1200g or 2.292 x 1012cells. 
3.Used maximum rate of 350mg/day (HAWKER, 1993). 
Table 4.2.2.1: Removal rates for the three reactions and the upper bound 
concentratio
 
Without information of the toxicity levels
fu
concentration conditions at which the body operates, the hepatoma cells appear to 
exhibit reaction rates that are in excess of those for the normal liver. Under these 
circumstances, the obvious option would be to take into account the anecdotal mass 
of cells quoted in the literature by various researchers and clinicians to be compatible 
with preserving life and designing the reactor for this mass of cells. 
 
Assuming that 20% of hepatocytes mass is required to sustain life, the mass of cell
to
conditions of the liver, we have attempted to design our reactor such that flows and 
pressure drops through the reactor are as close as possible to those of a normal 
functioning liver. To this end, the flow rate (Q) used is 300ml/min (normal arterial 
delivery to the liver). The pressure drop across the hepatocytes in the liver is 9mmHg 
(1200 Pa). Pressure drops across 
th
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4.2.3. Desig
 
The first ques s e rea
The constraints on the reactor design inc miting the amount of priming blood 
ti t a id r 
volume should lie som   
d t  volumes ( p lated cells + priming blood). 
For a packed bed reactor design, the volum  the reactor is just the volume of the 
e.  
tics 
ither reactor configuration would be feasible. However external mass transfer in the 
is dimensionless. 
herefore, the fractional volume of a bed occupied by solid material is (1-e) 
n Specifications 
tion one must ask is: What pecifications must th
lude li
ctor meet? 
from the pa ent to 500ml. This is se t a maximum. For a flu ised bed reacto
configuration, the reactor ewhere between the packed bed
volume an he expanded bed microenca su
e of
encapsulated cells incorporated, assuming a bed voidage of e=0.4. Secondly, the 
design should ensure that the pressure drop across the bed is as small as possibl
 
How do we design the reactor to ensure that it meets these specifications?  
Since we are not diffusion limited but rather limited by the intrinsic cell kine
e
reactor would be better in a fluidised bed reactor than a packed bed reactor.  
 
For the design of a fluidised bed reactor, the parameters that are available for the 
designer to choose and optimise include the geometry or dimensions of the reactor, so 
the length of the bed (L), the cross sectional area of the bed (A) and the voidage or 
bed expansion during fluidisation (e). e is the fraction of the volume of the bed not 
occupied by solid material and is termed the fractional voidage. It 
T
(COULSON & RICHARDSON, 1960). 
 
For the design of a packed bed reactor, the voidage is determined by the shape of the 
particles in the reactor. Since our beads are spherical in shape, they would probably 
assume the loosest form of packing with e = 0.4. The flow rate is the choice of the 
designer. Other parameters available for optimisation include the reactor geometry, L 
and A, and the pressure drop (∆P) across the bed. 
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4.2.4 Is a Fluidised Bed Reactor Design Feasible for Clinical Application? 
ger, 
ing 
lood (500ml).  
 the maximum blood volume allowable is 500ml, the Vmax for the reactor would be 
 
L and A are dependent on the aspect ratio (L/D) of the reactor vessel. A lon
thinner geometry is preferred to a shorter fatter type for better flow properties. The 
voidage is dependent on the pressure drop across the bed. Initially spheres in a bed 
would assume the loosest possible mode of packing (COULSON & RICHARDSON) 
therefore emin =0.4 (bed initially assumes packed bed configuration). 
 
The range of allowable reactor volumes can be calculated from the volume of beads 
and the volume of blood required constrained by the maximum volume of prim
b
Vbeads = 246 ml 
Assuming e = 0.4 
Vmin = 410 ml for the reactor, implying that Vblood = 164 ml 
 
If
the sum of the bead and blood volume, i.e. 746 ml. Therefore the allowable range of 
reactor volumes is given by 410 < Vreactor ≤ 746 ml. The maximum voidage can be 
calculated using the maximum allowable volume of the reactor, Vmax as follows: 
67.0
_ ==
m
bm
V
VVe .                                                                              Equation 4.2.4.1 
where Vb refers to the volume of the beads or spheres containing hepatocytes. 
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The pressure drop across the fluidised bed is constant irrespective of increasing 
elocity. To calculate the pressure drop at minimum fluidisation, the minimum v
fluidisation velocity (umf) must first be calculated. The minimum velocity, which will 
produce fluidisation if flow conditions within the bed are streamline, is obtained by: 
 
( )
gd
e
eu smf µ
ρρ −
⎟⎟⎠
⎞
⎜⎜⎝
⎛
−=
23
1
0055.0                                                       Equation 4.2.4.2 
=mfu 0.000191 m/s 
y is known and using the area just calculated, the reactor length, L, 
n b d. Pressure drop is related to the bed voidage and reactor length as 
Since the flow rate through the reactor is defined as 300 ml/min, the area of the 
reactor can be computed from Q = umf A. The volume of the reactor at minimum 
fluidising velocit
ca e calculate
follows: 
( )( )geP s ρρ −−=− 1                                                          l
∆               Equation 4.2.4.3 
 
 
 
 
 
 
 
 
Figure 4.2.4.1: Fluidised bed reactor configuration and specifications 
 
 
What would this reactor look like at incipient fluidisation? 
                                                    
Reactor Specifications  
Reactor Volume 410 ml 
Bead Volume 246 ml 
Number of cells 4.58x1011
Reactor Area 0.026 m2
Reactor Length 16 mm 
Reactor Diameter 183 mm 
Flow rate 300 ml/min 
Velocity (umf) 0.191 mm/s 
Pressure Drop 0.01 Pa 
L/D 0.08 
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From these quick and simple initial calculations, one can see that the fluidised bed is 
not the most feasible option. If one were to increase the voidage, hence the bed 
volume, the area of the reactor would increase by a greater amount than the length. A 
fluidised bed reactor is meant to be long and thin, i.e. L/D≅10, not short and broad as 
 shape adds problems associated
concentrations through the reactor.  
 
al between the fluid in the reactor and the particles being fluidised. Even 
though this reactor type is characterised by better mass transfer and temperature 
control, it is not essentia
 transfer and temperature 
dised bed, but since we are not diffusion limited this 
 are lim ic cell kinetics. Therefore, the 
actor we design should h ch that t
ay be increased at the des cian’s will. 
.2.5. Is a Packed Bed Reactor a Feasible Design for a Hybrid Artificial Liver 
Reactor? 
he feasibility of this react ation will be d  initial calculations 
sing the design constrain estimates s available to the 
esigner. The volume of th ermined by the volume of beads required 
ith a bed voidage, e=0.4, reactor = 410 ml. The flow rate is set at 300 ml/min. 
or geometry, L 
this  with fluid flow and inhomogeneous 
This result is not unexpected since the bead density is approximately equal to the 
blood density. This results in the extremely small minimum fluidisation velocity (umf). 
Velocities cannot be enhanced very much as this would result in entrainment of the 
microcapsules at the top of the fluidised bed. Ideally, one would want a larger density 
differenti
l that our reactor is a fluidised bed.  
 
A packed bed reactor does not have the exceptional mass
control characteristics of the flui
is ited by the intrins not a issue for us. We
re ave scalability su he number of cells incorporated 
m igner’s or clini
 
4
 
T or configur etermined by
u ts and initial of parameter
d e reactor is det
 i.e. Vw
The only parameters available for the designer to optimise are the react
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and A, and the pressure drop (∆P), across the bed, which increases as the velocity of 
blood perfusing through the bed increases. 
 
Since reactor volume is the product of the reactor area (A) and reactor length (L) 
which can both be written in terms of the diameter, and assuming an aspect ratio of 
L/D =10 the geometry of the reactor can be computed yielding: 
o = ρu0 the pressure drop 
cross the bed may be calculated using the Blake Kozeny equation (BIRD, 
 
A = 1104 mm2
L = 375 mm 
D = 37.5 mm 
 
The velocity (u) through the bed is then computed from Q = u A yielding a velocity 
of 4.53x10-3 m/s. If we assume the flow through the packed bed is laminar as 
10)1)(/( 1 <− −eGD os µ  (2.38 for these conditions) where G
a
STEWARD & LIGHTFOOT, 1960): 
 
2
32
)1(150 e
eD
L
Pu so −
∆= µ                                                                         Equation 4.2.5.1 
∆P = 6045 Pa (45.35 mmHg) 
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 What does this reactor look like? 
                                                                             
Figure 4.2.5.1: Packed bed reactor configuration and specifications 
% of liver mass is required to sustain life, we 
re able to design the reactor with the specifications above. This reactor only requires 
a blood volume of 164 ml. This implies that the priming volume of blood for the 
reactor itself is also on
highly desirable featu ed bed reactor volume can be increased by 67%. 
This allows for some flexibility as there is also a need to prime the lines leading to 
 the device with blood. 
 
 
Reactor Specifications  
 
 
 
Reactor Volume 410 ml 
Bead Volume 246 ml 
Reactor Area 1100 mm2
Reactor Length 375 mm 
Flow rate 300 ml/min 
Velocity 4.53 mm/s 
Pressure Drop 45.34 mmHg
 
 
 
 
 
 
 
 
Based on the assumption that only 20
Residence time 0.73 min 
L/D ratio 10 
a
ly 164ml. Therefore the apparent scalability of this reactor is a 
re as this pack
and from
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 Since lignocaine clearance was the rate limiting reaction of the three liver function 
ievable for various masses of cells. 
Figure 4.2.5.2: Reactor Rates for various amounts of cells (a), with the expanded 
region illustrating the infusion rate of lignocaine plotted on the Reactor Rate curve for 
various amounts of cells (b). 
tests, we examined the range of reaction rates ach
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From the graphs plotted above, 240g seems to be a reasonable estimate of cells. As 
 
teady st
e have achieved our desired goals by using an L/D ratio of 10. However, if we 
ished to decrease the pressure drop for any reason, this value could be decreased 
ithout any significant problems, which in turn allows further flexibility in our 
esign. 
the concentration builds up the reaction rate will increase to a new steady state. An 
important question that would need to be answered is what the maximum tolerable
s ate reaction rate is. 
 
W
w
w
d
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4.3. DISCUSSION AND CONCLUSION 
 
This paper has raised some interesting questions, firstly about the reaction kinetic 
data available in the literature and secondly about the use of fluidised bed reactors as 
ratory with that of normal cells obtained in the literature. We would then have 
tion based on the liver function that required the most cells to 
dotal reports suggest that flow rates used in dialysis 
machines range between 300 and 600 ml/min of whole blood. We wanted to calculate 
the flow rates that would correspond with the reaction rates for normal liver cells and 
base our reactor flow rate on those rates, the aim - to mimic as close as possible the 
in-vivo environment. Incompleteness in the data from various literature sources 
resulted in us abandoning this route. 
 
The approach taken assumed approximately 20% of liver hepatocyte mass was 
essential to keep a patient alive, and therefore the reactor design could be based on 
this cell mass. Process synthesis methodology was then applied to the reactor design 
process. It was always the intention of this research group that a fluidised bed reactor 
would be the best reactor type to incorporate the encapsulated hepatocytes for all the 
various properties of this particular reactor type. From the initial calculations, we 
found that this was not the most feasible option as the reactor geometry was contrary 
to the desired long and thin configuration (L/D ~10). Scalability of this reactor would 
result in non-feasible clinical applications based on the area and size of the bed that 
would result, as well as from the volume of priming blood that would be needed.  
 
bioartificial liver devices.  
 
Initially, our attempt was to calculate the number of cells required for use in our 
hybrid artificial liver reactor (HALR) based on a comparison of rate data obtained in 
the labo
used the limiting reac
base our reactor design on. Anec
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The main reason that a fluidised bed reactor will not work for this application is that 
e density of the blood. This implies 
ould have to increase to accommodate this 
during fluidisation remains constant. This 
reactor geometry and higher achievable 
icial velocities. 
ould be so minute that the shear stress on the beads are 
insignificant.  
 
the density of the microcapsules is very close to th
that small increases in velocity could result in entrainment of the beads, or velocities 
exceeding terminal velocity. As the velocity through the bed increases, the bed would 
expand such that the area of the reactor w
increasing velocity, as the pressure drop 
would result in a worse reactor geometry. 
 
If however we were mass transfer limited, which we believe is not the case, and there 
was really a need to use a fluidised bed reactor, the density problems could be solved 
in one of two ways. The first option would be to make the beads heavier. This could 
be achieved by encapsulating a dense material (e.g. metal filings) together with the 
cells. To avoid any unfavourable reactions of the cells to the denser material, the 
material could first be microencapsulated then encapsulated with the cells into a 
bigger bead. This would create a more favourable density differential between the 
beads and the blood, resulting in better 
superf
 
The other option would be to make the beads less dense so that they float in the blood 
and then fluidise downwards. This could be achieved by trapping air bubbles in the 
alginate/ cell suspension used to form the microcapsules.  
 
Based on simple calculations performed we were able to ascertain the non-feasibility 
of a fluidised bed reactor as a bioartificial liver reactor. There are other researchers 
however who have proposed the use a fluidised bed reactor (BARBE, DAVID & 
LEGALLAIS, 2002) and have gone further to determine how the motion in a 
fluidised bed affects the mechanical properties of the beads. The flow rates and 
superficial velocities w
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The other option of course would be to consider an alternate reactor type such as a 
packed bed reactor. 
 
We then proceeded to determine the feasibility of a packed bed reactor. Initial 
calculations yielded a feasible reactor design. The specifications of the reactor 
proposed were consistent with the clinical requirements as stated in the literature. The 
flow rate through the packed bed was the same as the arterial delivery to the liver, Q 
 300ml/min. The pressure drop through the bed was not as small as would have been 
hage complications (LANGER, 1982). Therefore, our research 
roup has undertaken the development of a heparin bioreactor (JOSHUA, 2003), 
tificial liver reactor, which 
ould be based on heparin anti-coagulated whole blood. Since heparin requires 
ll lines, as this may ultimately prove to be the factor that makes such 
actor design using transformed cells unacceptable. 
=
preferred but essentially not too harsh a pressure drop for the blood or the 
hepatocytes. Our HALR only requires a priming volume of 164 ml, implying that 
scalability is not a problem with this device. If however mass transfer was the rate 
limiting process, one would struggle to enhance mass transfer between the blood and 
microcapsule membrane in this type of reactor. 
 
Extracorporeal devices perfused with whole blood require the patient to be 
heparinised to prevent clotting in the device. However, heparinisation of the patient 
often leads to haemorr
g
which can be used as part of the clinicians’ armament when treating patients with 
extracorporeal therapy. One of the most salient benefits of the development of such a 
reactor is that is can be used in conjunction with our ar
w
metabolism by the liver, the heparin bioreactor would remove this added metabolic 
burden from an already decompensated liver. 
 
The in vitro studies and calculations performed during this research, suggest the 
feasibility of a hybrid artificial liver. However, prior to any extension of the research 
to clinical tests, an in depth risk analysis would need to be conducted on the use of 
transformed ce
re
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5. CO
 
Desig  
disciplines
biological al variables available to the 
esigner within each of these areas was necessary. In order to answer those questions 
at would allow us to determine the parameters available to the designer, a high-
level systems approach to the problem being researched was adopted. Throughout the 
course of this thesis, the reader may have found that certain areas could have been 
researched much further but were not. The main reason for this is that only those 
factors that contributed to the design of the reactor were explored. For example, the 
biological component we chose to incorporate in the reactor was a transformed liver 
cell line. Further research could have been conducted to determine the best cell line to 
use. We could have made the topic of the thesis a comparison of cell lines and their 
kinetics, but this was not the focus of this work. Our experiments and development 
was aimed at determining the critical factors in the design of the reactor. Research 
terminated at determining the functional integrity of the selected cell lines and 
selectivity of the reactor design to these cell lines. 
 
We selected the HuH-7 and HepG2 transformed hepatoma cell lines as possible 
candidates for incorporation into the reactor. Results demonstrated that both cell lines 
exhibited liver functionality with respect to three pre-selected liver function tests. 
Furthermore, the intrinsic cell kinetics determined for both cell lines did not differ 
significantly. From this, we concluded that it was probable that the reactor design was 
not sensitive to the type of cell line chosen. Therefore more cell lines were not tested. 
 
NCLUSION OF THE THESIS 
ning a hybrid artificial liver reactor required investigation into various 
. Given that the reactor being developed is a chimera of both synthetic and 
components, an understanding of the critic
d
th
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Indirectly, we have also developed a quick screening technique that other researchers 
an use for choosing a biological component for a bioartificial liver (BAL). Firstly 
order to determine the saturation 
oncentrations of the cells as well as the metabolic activity at these high 
c
what we have found which was also determined by various other researchers, was 
that these cells are more than adequate at performing ureagenesis. The rates at which 
our cells remove lignocaine from solution is almost comparable to the in vivo average 
liver cell rates.  
 
Metabolic reactions using the anionic carrier pathway, such as the conjugation of 
bilirubin were found to have the fastest reaction rates when compared to normal liver 
cells (with respect to all three liver function tests). So as a first pass in choosing a cell 
line, the bilirubin functionality should not be the first functionality test conducted. 
Furthermore, the accumulation of bilirubin per se is not a life threatening condition in 
an adult. Various alternate therapies are available to the clinician to deal with the 
conjugation of bilirubin such as plasma exchange therapy and exposure to UV light.  
 
We chose to look at liver functionality for the three tests across a wider concentration 
range, extending beyond the Cmax i.e. the concentration of the substrate in blood that 
would have to be removed. This was done in 
c
concentrations. The results obtained were most interesting. It seems that high 
concentrations of substances that medical practitioners regard as toxic to patients are 
not toxic as such to the liver cells themselves. This is evidenced by the increasing 
reaction rate obtained corresponding to an increasing reactant concentration. Another 
hypothesis that would explain these findings is that the cells tested are tumoregenic in 
nature and therefore inherently highly active, therefore capable of high reaction rates. 
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These findings would lead one to believe that the normal liver cells in the body 
operate at a much lower rate than they are capable of. This would imply that there is a 
lot of redundancy built into the liver. At normal substrate concentrations, the liver 
operates at a lower reaction rate. Due to liver disease or diminished liver capacity, the 
concentrations of these substances could be expected to increase and therefore a new 
higher steady state concentration and higher reaction rate could be established in the 
ver. This hypothesis is validated by the fact that loss of two thirds of liver 
 
f McGill University’s laboratory. Encapsulating the cells allows the designer the use 
ontrol. In this case, that would be the intrinsic reaction rate of the cells. 
 
li
functionality does not lead to patient death. 
 
Subsequent to establishing the nature of the biological component, the next step in the 
reactor development was finding a way to incorporate the cells into the reactor, while 
simultaneously immuno-isolating them and overcoming the drawbacks of previous 
BAL designs such as mass transfer limitations and cell volume constraints. This was 
achieved by employing the microencapsulation technique learnt in Professor Chang
o
of whole blood perfusion instead of plasma reducing the number of extracorporeal 
devices a patient would have to be connected too. The capsular membrane however 
adds a barrier to the diffusion of substrates, products and nutrients to the liver cells. 
 
The first step in designing the reactor is determining what the rate-limiting step is. 
Which reaction would the designer prefer to be rate limiting? Obviously, it would be 
the one that the designer has the most control over, such as external mass transfer. 
This would be the best-case scenario as the reactor can be redesigned or the flow 
better designed to facilitate better mass transfer should mass transfer be rate limiting. 
However, a well-designed reactor would be limited by a rate beyond the designer’s 
c
 
103
The results obtained in the second chapter revealed the rate-limiting step to be the 
intrinsic cell kinetics. The capsular membrane was found to not significantly hinder 
the transport of material across the membrane. Therefore, we were not diffusion 
limited. Not much can be done to enhance the intrinsic cell kinetics except to increase 
the number of cells in the reactor. This may be achieved by increasing either the cell 
loading of the beads, the bead diameter or the number of beads incorporated into the 
reactor. Since the bead diameter is one of the design constraints, the two other options 
are the only avenues available for the designer’s exploitation. Another implication of 
ese findings is that the designer does not have to design for optimising the bead 
t 
eir maximum rate in the device. 
nced by the 
ct that the encapsulated cells could be kept alive for at least six days.  
 
th
membrane. 
 
The rate-limiting step was determined by comparing the mass transfer half-life to the 
intrinsic cell kinetic half-life for the same set of conditions. The maximum rates 
obtained for the three reactions were used to do this computation. One would expect 
that at these high reaction rates mass transfer might be the limiting factor in the 
process. What we found was that even at these elevated rates of reaction, the mass 
transfer was not limiting. Therefore, one could infer that in reactor operation the mass 
transfer would be much better as the cells would most probably not be at reacting a
th
 
The type of substrates that would have to cross the capsular membrane would include 
molecules ranging from the small size represented by urea through to bigger 
molecules of the size of lignocaine. The membrane produced by Chang’s method 
does not hinder the diffusion of these substances in any way as is evidenced by mass 
transfer data obtained in the laboratory discussed in Chapter 2. Oxygen should not 
have a problem diffusing through the membrane either. This was evide
fa
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The reactor configuration found to be most feasible for a HALR was the packed bed 
reactor because the microcapsule density is very close to that of the density of blood. 
Thus, if one wanted to take the fluidised bed approach, the superficial velocities 
achievable would be too low. Since the velocity is related to the flow rate, which is in 
turn related to the reactor geometry or dimensions, an increase in flow rate would 
result in an increase in reactor diameter. The optimum shape of a fluidised bed reactor 
is long and thin with an L/D of approximately 10 and not short and broad. Therefore, 
the packed bed option was investigated. A packed bed reactor does not have the 
exceptional flow characteristics of a fluidised bed reactor, but since we are not mass 
transfer limited this was not regarded as an issue of concern. 
 
The findings from the laboratory research are all very interesting in terms of reactor 
design. Traditionally, a chemical engineer will usually design a reactor based on 
maximum rates possible. Obviously the ultimate Chemical Engineer does not concur, 
as this is obviously not the case with the liver in the body (Refer to Table 5.1). It 
seems as though a tremendous amount of redundancy has been built into the design 
(of the liver) allowing for the ability to respond to all sorts of situations. 
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Normal Liver Cells 
Reaction Rates 
HuH-7 Maximum 
Reaction Rates 
HepG2 Maximum 
Reaction Rates 
Concentra
in Blood 
tion 
Ammonia 
Metabolism 
2.08nmol/106cells/min 29nmol/106cells/min 35nmol/106cells/min 100 µmol/l 
Lignocaine 
Uptake 
4.53 x 10-12 
mol/106cells/min 
0.22 x 10-9 
mol/106cells/min 
0.178 x 10-9 
mol/106cells/min 
2-6 µg/m
(Plasma 
concentra
l 
tion)
99mTc-
DISIDA 
Uptake 
(Data unavailable in 
similar units for 
comparison) 
6.10 x 10-8 
Ci/106cells/min 
4.50 x 10-8 
Ci/106cells/min 
Rate 
1.67x10-6 
constant (k) 1.609x10-8 min-1 0.0017 min-1 0.00255 min-1
Ci/ml 
(Plasma 
concentration)
(Based on 
half life) 
Table 5.1: Comparison of reaction kinetics between normal liver cells and the 
transformed hepatoma cell lines for the three liver function tests. 
 
It seems that liver cells are capable of higher rates of reaction concomitant with high 
substrate concentrations, i.e. higher than those quoted in column 5 of Table 5.1. What 
is unclear however is the range of substrate concentrations the body could actually 
tolerate. 
 
What we discovered in our research is that the design of an artificial liver is not a 
problem in terms of achieving removal (i.e. reaction rate). The liver cells are able to 
operate at much higher reactions rates than occurs in the body. In order to function at 
such high rates, the concentrations of the substrates might be in the range regarded as 
toxic to the rest of the body. What is required is to test the whole system, which 
would imply the whole body to determine concentrations which are toxic to the body 
over the short term. 
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If you designed the liver independent of the body, you would only need a small 
ount of c axi tes, rres
concentratio xic to th dy a l cells w
Th  0
r rate based on 240g of cells but whether these higher 
o i  to be susta a s an open
 
In clusio s sh packed bed configuration is a feasible 
type including t ells r t the  
needed for the adequate removal of substances required for artificial liver 
am ells operating at m
ns might be to
mum reaction ra
e rest of the bo
but since the co
arger mass of 
ponding 
ould be 
required. 
operate efficiently at a highe
erefore, even though a liver contains 12 0g of cells our HALR can 
concentrati ns allow l fe ined rem in  question. 
 con
reactor 
n, our research ha
 capable of 
own that a 
he number of c equired to effec reaction
rate 
support. 
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APPENDIX A – HPLC METHOD FOR DETERMINING LIGNOCAINE 
 
SPECIMEN: 
 
A 5ml sample. 
 
EQUIPMENT AND MATERIALS: 
PLC system with UV detector and integrating facilities. 
. Vortex mixer. 
. Centrifuge. 
. Waterbath at 40ºC. 
5. Assorted pipettes. 
 
MATERIALS: 
 
1. Water ųBondapak C18 (10ųm) HPLC column 300 x 3.9mm ID – Water Cat.No. 
2. Drug Free Serum – BioRad Cat.No. 
3. Acetonitrile HPLC grade 
4. Potassium dihydrogen phosphate- 
5. Dichloromethane HPLC grade 
6. Trimethoprim 
7. Lignocaine hydrochloride 
8. Sodium hydroxide 
9. Sterilin 15ml PTFE tubes 
10. Whatman Phase Sep filter papers 
11. Milli-Q water 
 
EQUIPMENT: 
 
1. A H
2
3
4
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REAGENTS: 
 
1. 0.05M Potassium dihydrogen phosphate pH 4.0: 
Weigh out 6.805g of potassium dihydrogen phosphate and dissolve in ± 700ml 
beaker. 
Adjust pH to 4.0 with phosphoric acid. 
sk and make up to volume with water. 
 
ase:
water in a 
Transfer to a 1 litre volumetric fla
2. Mobile ph  
Mix 860ml of the above 0.05M buffer with 140ml acetonitrile. 
 
m dihydrogen phosphate pH 2.8:3. 0.05M Potassiu  
.805g of potassium dihydrogen phosphate and dissolve in ± 700ml 
ith phosphoric acid. 
Transfer to a 1 litre volumetric flask and make up to volume with water. 
4. 0.25M Sodium hydroxyde:
Weigh out 6
water in a beaker. 
Adjust pH to 2.8 w
 
 
 
tandard:
Weigh out 1.0g of sodium hydroxide pellets and dissolve in 100ml water. 
5. Trimethoprim Internal S  
nd dissolve in 1 litre of water. 
 
d:
Weigh out 15mg of trimethoprim a
CALIBRATION: 
1. Lignocaine Stock Standar  
e solution. 
 
Dilute the lignocain
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QUALITY CONTROL: 
. Reconstitute 1 bottle each of carotene serum control level 1 and 2 with 2.0ml 
hen not in use. 
 
PRO
SETTING UP OF INSTRUMENTS: 
1. oop is correct - 
20ųl 
parafilm. 
3. 
then set ESS to position 1 for intermittent sparging. 
4.  using syringe supplied. 
 
COMPUTER AND SOFTWARE: 
2. 
3. Maximise Program Manager. 
k. 
5.  appears. 
FILE EDIT USER VIEW CONTROL RUN PEAKS PROCESS HELP 
Main Menu top row select “Control”. 
t “Dev. Control on System 2” – Click ON. 
8. 
9. When pump control screen appears set flow rate at 0.5 ml/min. 
10. From Borwin Main Menu top row select “RUN”. 
11. Then click ON “Working List”. 
12. then click ON “Working on System 2”. 
1
Milli-Q water. 
Allow to stand for 10 – 15 minutes, then mix gently. 
Store in freezer w
CEDURE – STEPWISE: 
HPLC: 
Install correct column for lignocaine and check that sample l
2. Place reagent lines into bottle, seal top with sheet of 
Switch on helium cylinder and ESS and bubble helium through mobile phase 
for a few minutes, 
Switch on pump and prime mobile phase
1. Switch ON Computer. 
At the C:\ type in WIN 
4. Select Borwin V icon and double clic
Double click on next Borwin icon – Borwin loads and Main Menu
6. From Borwin 
7. Control drop down menu selec
Click ON “HPLC PUMP”. 
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13. When work list screen appears, select the  (open file icon) top left hand 
14. at appears, click ON “ligno”. 
15.  new parameters and 
 save new list. 
16. Click ON “Start Acquisition” icon. 
itch on detector and allow to go through set-up program. 
3. t AUFS – set to “ENTER”. 
MET
. Add 50µl internal standard mixture. 
oxide. 
s. 
ane. 
9. 
 
 
 r into the INJECT position. 
corner and click ON. 
From the list th
The worklist from the previous run loads.  Edit list with
then click on  (close file icon) to
 
 
DETECTOR: 
1. Sw
2. Select λ wavelength button – enter 205nm – press “ENTER”. 
Selec
4. Press AITO ZERO to zero detector. 
 
HOD: 
1. Into a 5ml plastic test tube, pipette 0.5ml serum. 
2
3. Add 40µl of 0.25M sodium hydr
4. Vortex for a few second
5. Add 4.0ml dichlorometh
6. Vortex for 1 minute. 
7. Filter through a phase Sep filter paper. 
8. Place into a waterbath at ± 40ºC – and evaporate to dryness. 
Reconstitute with 300µl 0.05M potassium dihydrogen phosphate pH 2.8. 
10. Vortex for a few seconds. 
11. Draw 100µl into the injection syringe and load onto rheodyne injector. 
12. Switch the rheodyne injecto
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INTEGRATION: 
On main screen click 1. On  (open file icon) – a list of all files appears. 
romatogram appears in right hand 
3. S”. 
p down menu – select  (open file icon) 
and select “CAROT”. 
“Find peaks” on drop down menu – chromatogram will be integrated. 
atogram will be 
ION: 
 area ratios for all standards and samples. 
f standard x concentration of standard 
lculated by using computer program HPLC. 
Please Note: Values may be given in nmol/L on insert but results are 
re
D
0.19 – 1.58 µmol/L. 
 
2. Highlight appropriate file name – a sample ch
corner – press. 
When chromatogram has loaded, click ON “PEAK
4. Click On “Peak parameters” on dro
5. Click ON 
6. Baseline and peak starts and ends may need adjustment. 
7. Select “PRINT” icon to print report – Please Note Chrom
printed as seen on screen! 
8. Close chromatogram. 
 
CALCULAT
1. Note down the area values on worksheet. 
2. Calculate the analyte area/internal std
3. Calculate results as follows: 
 Ratio of unknown ÷ ratio o
4. Alternatively results can be ca
 
ported in µmol/L. 
ivide result by 1000. 
 
PROCEDURE NOTES: 
Reference Ranges: 
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APPENDIX B – METHOD FOR CELL ENCAPSULATION 
Cells (h
Cells added to  alginate. 
(working concentration of 6 cells/ml. 5ml 
solution). 
 
3) Extrude solution with a syringe infusion pump through droplet generator  
(Air flow rate = 2-3 l/min   Infusion Rate = 0.28 –0.39 ml/min). 
 
4) Gelation upon contact with 300ml 100mM receiving solution. 
(Height between jet and CaCl2 >= 20cm) 
 
5) Microcapsules are cured in CaCl2 solution for 15 minutes. 
 
6) Microcapsules are washed at least thrice in saline. 
 
7) 5ml microcapsules + 80 ml of 50% Poly-L-lysine for 20 mins. 
 
8) Microcapsules strained and washed with saline at least thrice. 
 
9) Immersed into 200ml of 0.2% Sodium Alginate for 5 min. 
 
10)  Washed and immersed in 200 ml of 50mM Sodium Citrate for 6 min. 
 
11)  Washed and stored in culture medium for future use. 
 
 
 
1) epatocytes) washed with buffered saline (medical saline 
2) 4% stock solution of sodium
2% alginate solution containing 1x10
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